

VALLO VARIK

Stringent Response
in Bacterial Growth and
Survival



VALLO VARIK

Stringent Response
in Bacterial Growth and
Survival



Institute of Technology, Faculty of Science and Technology, University of Tartu,
Estonia

Dissertation was accepted for the commencement of the degree of Doctor of
Philosophy in Biomedical Engineering on August 30, 2017 by the joint council
of the Curriculum of Engineering and Technology of Tartu University

Supervisors: Tanel Tenson, PhD
Institute of Technology, University of Tartu, Estonia


Vasili Hauryliuk, PhD
Department of Molecular Biology, Umeå University, Sweden

Reviewer: Tiina Alamäe, PhD
Institute of Molecular and Cell Biology, University of Tartu,
Estonia

Opponent: Gregory Bokinsky, PhD
Department of Bionanoscience, Delft University of
Technology, The Netherlands

Commencement: Auditorium 121, Nooruse 1, Tartu, Estonia, on October 2nd,
2017, at 14:15

Publication of this thesis is granted by the Institute of Technology, Faculty of
Science and Technology, University of Tartu and by the Graduate School in Bio-
medicine and Biotechnology created under the auspices of European Social Fund.



European Union
European Social Fund



Investing
in your future

ISSN 2228-0855
ISBN 978-9949-77-545-3 (print)
ISBN 978-9949-77-546-0 (pdf)

Copyright: Vallo Varik, 2017

University of Tartu Press
www.tyk.ee

TABLE OF CONTENTS

LIST OF PUBLICATIONS	6
LIST OF ABBREVIATIONS	7
INTRODUCTION	8
1. OVERVIEW OF LITERATURE	9
1.1. Growth	9
1.1.1. Balanced growth and its rate	10
1.1.2. Exponential phase	12
1.1.3. Stationary phase	14
1.1.3.1. Transition	14
1.1.3.2. Duration	15
1.1.3.3. Exit	17
1.2. The stringent response	18
1.2.1. RelA	19
1.2.2. SpoT	21
1.2.3. The rest of the RelA/SpoT family	23
1.2.4. (p)ppGpp in growth and survival	25
1.2.5. (p)ppGpp in virulence	26
AIMS OF THE STUDY	28
2. RESULTS AND DISCUSSION	29
2.1. Relationship between bacterial growth, action of antibiotic and innate immunity (I)	29
2.2. The role of stringent response in growth resumption (II)	30
2.3. A quest for a stringent response inhibitor (III)	33
CONCLUSIONS	35
LIST OF REFERENCES	36
SUMMARY IN ESTONIAN	54
ACKNOWLEDGEMENTS	57
PUBLICATIONS	59
CURRICULUM VITAE	97
ELULOOKIRJELDUS	99

LIST OF PUBLICATIONS

The thesis is based on the following publications that will be referred to in the text by their Roman numerals:

- Ref. I** Putrinš M, Kogermann K, Lukk E, Lippus M, **Varik V** & Tenson T (2015). Phenotypic heterogeneity enables uropathogenic *Escherichia coli* to evade killing by antibiotics and serum complement. *Infection and Immunity* 83, 1056–67.
- Ref. II** **Varik V**, Oliveira SRA, Hauryliuk V & Tenson T (2016). Composition of the outgrowth medium modulates wake-up kinetics and ampicillin sensitivity of stringent and relaxed *Escherichia coli*. *Scientific Reports* 6, 22308.
- Ref. III** Andresen L*, **Varik V***, Tozawa Y, Jimmy S, Lindberg S, Tenson T & Hauryliuk V (2016). Auxotrophy-based High Throughput Screening assay for the identification of *Bacillus subtilis* stringent response inhibitors. *Scientific Reports* 6, 35824.

* Equal contribution

My contribution to the papers:

- Ref. I** Performed the experiments to set up the methodology for serum killing of the bacteria and flow cytometry assays and participated in writing the manuscript.
- Ref. II** Performed all the experiments, except the ampicillin killing assay, analyzed the data, participated in writing the manuscript, and as a co-corresponding author prepared the submission to the journal.
- Ref. III** Performed the experiments adjusting the assay to high throughput layout, wrote the automated data analysis script, analyzed the data and participated in writing the manuscript.

LIST OF ABBREVIATIONS

ACP	Acyl Carrier Protein
CFU	Colony Forming Unit
CRP	cAMP Response Protein
csr	Carbon storage regulatory (network)
GASP	Growth Advantage in Stationary Phase (phenotype)
HD	Histidine-Aspartate (conserved residues in active center of RSH enzymes)
HPF	Hibernation Promoting Factor
HTS	High Throughput Screening
MIC	Minimal Inhibitory Concentration
ppGpp	Guanosine tetraphosphate i.e. guanosine-5',3'-bispyrophosphate
pppGpp	Guanosine pentaphosphate i.e. guanosine-5'-triphosphate-3'-diphosphate
(p)ppGpp	ppGpp and/or pppGpp
RMF	Ribosome Modulation Factor
RSH	RelA/SpoT Homologues
SAH	Small Alarmone Hydrolase
SAS	Small Alarmone Synthetase
SCDI	Stationary phase Contact-Dependent Inhibition
UPEC	Uropathogenic <i>Escherichia coli</i>
VBNC	Viable But Nonculturable

INTRODUCTION

*In the struggle for survival, the fittest win out at the expense of their rivals
because they succeed in adapting themselves best to their environment.*

Charles Darwin

Bacteria, free living single cellular organisms, are tightly exposed to their environment. Both biotic and abiotic forces shape their fate. During the time of plentiful, many bacterial species are able to grow astonishingly fast. This itself, however, leads to a rapid and inevitable change – the bacteria exhaust the growth supporting potential of the environment.

In changing environments, in order to adjust and to survive, several mechanisms are in place. One of the most widespread bacterial strategies against perturbations and survival during harsh times is a mechanism called the stringent response. In case of a bacterial infection, not surprisingly, the host is hostile. As expected, the stringent response is important for pathogenic bacteria both to establish an infection and to endure. Therefore, the stringent response is not only of great intellectual interest of a few, instead, it affects the general public, in health and in sickness. That is not to say, in life and death.

In the following pages, I will describe the life-style of bacteria in growth and survival with an emphasis on the role of the stringent response. No attempt was made to be exhaustive – way more is known about the subjects that could contain in the thesis – I will portray just inasmuch as is necessary to support the inquiries taken and follow the results obtained. As it is often the case in studies of bacterial physiology, although contemporary science is advancing into new bacterial species at ever increasing pace, the treatise will be heavily biased towards *Escherichia coli*. It becomes also obvious very quickly – out of all the major biological processes, the author is most familiar with the translation.

1. OVERVIEW OF LITERATURE

1.1. Growth

This treatise is much about bacterial cell physiology in batch culture. It is non-sense to talk about cell physiology without specifying the strain and the growth conditions – the nutritional, chemical, and physical environment. The resulting growth of bacterial culture can be described by extensive or intensive properties (**Fig. 1**). Extensive properties include the amounts of different components of the culture – protein, DNA, RNA etc. Intensive properties describe the distribution of the extensive properties i.e. distribution of cells in terms of total protein, DNA, RNA content. Other most common intensive properties are cell size and age. During unrestricted growth, *extensive* parameters increase by the same factor over the time, this condition was aptly termed ‘balanced growth’ by Campbell (Campbell, 1957). It should be perhaps emphasized that studies of balanced growth cultures describe an average cell, yet individual cells can be very different. During steady state, however, the *intensive* parameters are invariant. Thus, steady state is the most strict term and implies both exponential and balanced growth. The sloppiest one of the three terms – in addition to balanced and steady state growth – is exponential growth, it implies, if anything, that cells were growing experimentally unperturbed. All that said, it is hard to find the homogeneous, unaltered environment necessary for steady, balanced or exponential growth of bacterial population in their natural environment.

Cell growth comprises of increase in cell mass followed by cell division. One of the most remarkable and well known features of bacteria is the speed at which they – though, of course, not all of the species – are able to grow and divide, in favorable environments. Laboratory *E. coli* can form two new daughter cells astonishingly fast, in 20 minutes. As pointed out by Postgate (Postgate, 1994), if it were sustainable for long periods of time, *E. coli* culture would equal the mass of earth in mere three days. Instead, cells eventually run out of nutrients – more generally speaking, change their growth environment – and slow down the growth. Now we encounter the next key feature of bacterial cells, their endurance to withstand stasis, long periods in harsh environments of little or no growth. Not only do they survive the specific starvation which they encounter, but develop resistance to other stresses, as if adhering to the Nietzsche’s “That which does not kill us makes us stronger”. An important aim as well as a direct measure of survival is the ability to resume growth when conditions become favorable.




Figure 1. The unrestricted growth of bacterial cultures can be described by extensive or intensive properties. Let us suppose that we are interested in the amount of DNA in the culture, which is our extensive property of interest. Let it also hold true that cells have been growing some time in the medium and when we finally start our experiment (T_0), one third of the cells have either one, two, or four chromosomes. For the sake of the brevity, therefore, the cells shown on figure describe the exact distribution of the chromosomes among cell population. The very distribution of chromosomes is our intensive property of interest. Then, one culture doubling time later ($T_{0+\tau}$), we observe that the number of cells has faithfully increased twice. If the amount of chromosomes, however, has increased by anything else than factor of two, the growth is unperturbed at most. If the number of chromosomes has, indeed, increased by factor of two, but the distribution of chromosomes has changed, the cells are in balanced growth. Only if the number of chromosomes has increased twice and the distribution of the chromosomes between the cells stays unaltered, the culture is growing in steady state.

Next couple of chapters will briefly visit the key features of bacterial cell growth and stasis survival of non-sporulating bacteria.

1.1.1. Balanced growth and its rate

When bacteria have adjusted to the growth environment, after some cell divisions, they achieve a balanced growth i.e. all cell constituents begin to increase by the same proportion over the same interval of time. This situation can be approximated for some time in laboratory.

In batch culture, unchanged environment is often an assumption which can be checked empirically by following the increase in cell mass – exponential increase of cell mass by at least factor of 10 is a good starting point. Obviously, not all changes in cell physiology can be detected this way. Because of the often imperceptible changes, it is safe to assume that all the properties of the cells remain the same only if the density of the culture is sufficiently low, a long before the growth is slowing down. Usually less than 10^8 cells per milliliter is safe.

Although balanced growth does not occur for long periods in natural environments, it is desirable to achieve it in laboratory conditions for one reason: it is highly reproducible. First, one can sample the culture at any time point during the balanced growth and the sample content is identical. Second, if you know the growth rate, a single measurement of DNA, mRNA, ribosome content and so on, will tell you the absolute rate of synthesis (e.g. femtograms/ bacterium/minute). Third, given its highly reproducible nature, it is the only way to *directly* compare the results from different laboratories (Neidhardt, 2006).

In balanced growth culture, bacteria divide asynchronously. Even if starting from a single cell and sustaining the environment unchanged, small deviations in division time (coefficient of variation around 20% (Schaechter *et al.*, 1962)) will inevitably result in an asynchronous culture. Measurements at the level of cell culture, therefore, represent an average over all cells. This average does not necessarily describe even the majority of the cells, in fact, if the property in question has a binomial distribution, average does not describe almost any cell in the population. Fortunately, given the cumulative action of components of complex systems – to which biological ones belong, even if dissected to the level of single molecules – the rising distribution of a feature can often be approximated by a normal distribution. Note that chemical processes, to which biological ones rely on, are multiplicative and therefore a log transformation is often necessary to this approximation of a normal distribution (Galton, 1879; McAlister, 1879).

Bacterial cells divide by a binary fission, an auto-catalytic first-order reaction for which the rate constant can be derived from a simple exponential equation. Therefore, we can calculate the number of cells (or, in fact, any extensive property of cell culture by):

$$N_t = N_{t_0} 2^n \tag{1}$$

Where N_t is the number of cells at a timepoint of interest (at time t), N_{t_0} is the number of cells at some previous timepoint and n is the number of doublings the culture has gone through, during the time interval ($\Delta t = t - t_0$). Next, n can be substituted by a time it takes to double, a doubling time, τ ($n = \Delta t / \tau$), or better yet, with a reciprocal of doubling time, growth rate μ ($n = \mu \Delta t$). After taking \log_2 and rearranging the equation, we arrive at:

$$\mu = \frac{\log_2 N_t - \log_2 N_{t_0}}{\Delta t} \tag{2}$$

It is simple and straightforward, however, some care should be taken to distinguish μ and τ from μ_e and τ_e , the latter two can be derived by starting from:

$$N_t = N_{t_0} e^n \tag{3}$$

or from:

$$\frac{dN}{dt} = \mu_e N \quad (4)$$

after rearranging and integrating (from t_0 to t), in μ_e .

Since μ_e is solved on base of e , it tells us *instantaneous* growth rate, i.e. how many times per hour does the culture increase e -fold (2.718-fold, unit: h^{-1}). Conventional μ – which can be denoted as μ_2 to distinguish it from μ_e and can be derived from the latter by simple division ($\mu_2 = \mu_e / \ln 2$) – is more intuitive to biologists, because it tells how many doublings are the cells going through per hour (unit: $\text{doublings} \times \text{h}^{-1}$). Both growth rate notations are in use and almost never specified. Hereafter, μ refers to conventional growth rate i.e. expresses doublings per unit of time.

1.1.2. Exponential phase

As we saw in last chapter, growth rate constant (μ), the only parameter to solve for quantitative description of balanced bacterial growth, is located in exponent of equation for binary fission ($N_t = N_0 2^{\mu t}$). Bacteria of unrestricted balanced growth, i.e. cells grow at maximum growth rate achievable in particular medium, are therefore told to be in exponential growth phase, sometimes the word logarithmic is used instead (**Fig. 2**). Note that for practical purposes, however, it is mostly impossible to tell a difference between exponential and linear growth during one division cycle – the difference is just too subtle. Only after a couple of divisions, the pattern emerges.

Given the condition of balanced growth, the macromolecular composition of exponentially growing bacterial cells, on average, has a universal correlation with growth rate. Faster growing cells have more RNA, protein, DNA, and the cells are larger (Schaechter *et al.*, 1958). In this relationship, with a growth rate as independent variable, the most rapid change is for RNA, followed by cell mass and protein abundance and the slowest increase is for DNA content. It follows that faster growing cells have a higher RNA-per-protein ratio, an important hint for the reasons of some of the observed phenomena. Indeed, faster growing cells are enriched in RNA because the intracellular content is shifted in favor of more ribosomes per cell. As a result, the RNA-to-protein ratio increases because ribosomes are composed of more RNA than protein (~65% RNA and ~35% protein; in contrast, average *E. coli* cell at 40 minute doubling time, 21% of RNA and 55% of protein (Neidhardt & Umberger, 1996)). The most common and long withstanding explanation for the positive correlation between the ribosome content and growth rate is that the speed of protein chain elongation by ribosome is kept maximal whenever possible (close to 22 amino acids/per second (Dennis & Bremer, 1974; Dennis & Nomura, 1974; Young & Bremer,

1976)) and thus, instead of making the ribosomes work considerably faster or slower, the cells adjust the amount of ribosomes. We will return to this question in chapter 1.2.2.




Figure 2. Bacteria of unrestricted balanced growth are growing exponentially. (A) When inoculated into a new medium, as described in chapter 1.1.3.3., cells often do not start to grow right away (first hour, doubling time, τ , is infinitely long), but when they finally do, the growth – followed here by measuring the culture turbidity at 600 nm – is exponential as is evident from the straight line in logarithmic scale ($\tau=20$ min). Rapid exponential growth, however, changes the composition of medium, upon which cells can assume some different growth rate ($\tau=40$ min) before they stop growing altogether ($\tau=\infty$). **(B)** Exactly the same growth curve as in (A), except plotted in linear scale. Importantly, most of the information contained in (A) is lost and, instead, experimentalist might be led to believe there is about two hour growth lag followed by exponential growth with a doubling time of 40 minutes.

In rich nutritious environment with less of an anabolic burden, *E. coli* cells can divide very rapidly – two new daughter cells are formed in 20 minutes. Yet the chromosome replication (called C period) itself takes about 40 minutes and cell division process (called D period) takes about 20 minutes in rapidly growing *E. coli* cells (Bapatnath *et al.*, 1998; Cooper & Helmstetter, 1968). In order to have cell division in every 20 minutes, therefore, cells start a new round of DNA replication before the previous round has been finished (Helmstetter & Cooper, 1968). This explains why there is more DNA in faster growing cells. It also implies that when *E. coli* is grown in rich medium (i.e. LB), for the chromosome region around the origin of replication the gene copy number, in some of the cells, is as high as 16 (Akerlund *et al.*, 1995; Hill *et al.*, 2012; Nielsen *et al.*, 2007). Finally, because the DNA replication is generally initiated when cells have acquired certain mass (Bapatnath *et al.*, 1998; Cooper, 1997; Donachie, 1968; Hill *et al.*, 2012; Wold *et al.*, 1994), cells with multiple rounds of replication must be larger. So, *E. coli* cells at 2.5 doublings/h are six times larger than when growing at 0.6 doublings/h (Schaechter *et al.*, 1958).

1.1.3. Stationary phase

1.1.3.1. Transition

During transition to stationary phase, the growth of bacteria becomes unbalanced. Some process – say, protein synthesis – becomes suboptimal, limiting, and slows down well before the others. This results in three things worth mentioning. First, the composition of the culture is changing and, therefore, sampling timepoints are not equal any more. Second, the culture composition depends on the particular circumstances of growth stop – i.e. starvation for carbon, or that for a nitrogen, accumulation of waste products and so on – each of which results in different culture composition and bacterial physiology (Peterson *et al.*, 2005). Variable combinations of circumstances can act simultaneously, further complicating the state of affairs. Finally, the cell-to-cell variability increases considerably, initially it is phenotypic, but eventually genetic heterogeneity will emerge, too (Finkel & Kolter, 1999).

If cells grow in a defined minimal medium, the run-out of a single essential component results in abrupt cessation of growth. In complex media, often of undefined composition, growth stop is usually more gradual as cells exhaust several components one after another (Sezonov *et al.*, 2007), also the pH might become unfavorable (Wilson *et al.*, 2003), upon which cells adjust and continue growing at slower rate, possibly in several subsequent steps, before final stop. In modern microbiologist's favorite medium, Lysogeny broth (LB), balanced growth can be disturbed already at OD₆₀₀ 0.3 (Fig. 2A), most probably when cells run out of residual glucose (LB is not supplemented with glucose, it originates, in variable amounts, from the yeast cell extract). Thus some experimentalist prolong the first, hopefully balanced growth phase by supplementing glucose to the LB.

Regardless the reasons for stasis, there are still some overarching principles common to cells entering the stationary phase: (i) the number of chromosomes approaches an integer; (ii) cells get smaller in size; (iii) active ribosomes are converted into inactive ribosome dimers. If the exponential phase environment supports fast enough growth to have several copies of chromosome (see chapter 1.1.2), then, during transition to stationary, new rounds of DNA synthesis are not initiated yet the elongation continues to termination. During that time, cells do not grow much – it is, after-all, during conditions that do not allow growth of cell mass – but do still divide, therefore, cells get smaller in size, this process is called reductive cell division (Lange & Hengge-Aronis, 1991a; Nyström *et al.*, 1996). Besides reducing the number of chromosomes and increasing the number of cells, it improves surface-to-volume ratio – all of which might improve survival. Resulting stationary phase cells can still contain several copies of chromosome, in case of rich complex medium up to 8 chromosomes, with 2 and 4 being the most common (Akerlund *et al.*, 1995; Boye & Løbner-Olesen, 1991).

Excess protein synthesis is curtailed by converting ribosomes into translationally inactive 100S dimers, owing to the concerted action of ribosome

modulation factor RMF (Wada *et al.*, 1990) and hibernation promoting factor HPF (Ueta *et al.*, 2005). 100S dimers seem to function as a inactive storage form of ribosomes (Wada, 1998; Wada *et al.*, 1990, 1995; Yamagishi *et al.*, 1993), energetically expensive molecular machinery, to be rapidly utilized whenever the conditions permit a rapid growth again (Aiso *et al.*, 2005; Yamagishi *et al.*, 1993). The importance of 100S ribosomes is further emphasized by the fact that during prolonged starvation, 100S ribosome dissociation is correlated with the lost viability of the cells (Wada, 1998). In addition to ribosome storage in 100S, rRNA becomes less stable as rRNA degradation is activated (Gausing, 1977; Hsu *et al.*, 1994; Maiväli *et al.*, 2013).

Much of the transition of cells into and survival throughout the stationary phase depends on the *rpoS* which encodes a master regulator, stationary phase and starvation specific sigma factor σ^S (Loewen & Hengge-Aronis, 1994). Sigma factors bind the core RNA polymerase to program the pattern of promoter recognition and thus direct the transcription at genome-wide scale (Österberg *et al.*, 2011). σ^S is close relative to the exponential growth phase sigma factor σ^{70} and, accordingly, the two factors recognize similar, but not identical promoters (Typas *et al.*, 2007). Directly and indirectly, RpoS activates about 10% of *E. coli* genes (Weber *et al.*, 2005). For example, the cells produced during reductive cell division (see above) are often coccoid in shape, which depends on BofA morphogene upregulated by *RpoS*, during entry into stationary phase (Lange & Hengge-Aronis, 1991a).

1.1.3.2. Duration

Besides numerous morphological changes – to name some: cells are smaller in size, the cell wall is more highly cross-linked, cytoplasm is condensed, and periplasmic space is increased (Huisman *et al.*, 1996) – stationary phase cells are remarkably resistant against different stress factors, such as high salt (Jenkins *et al.*, 1990), heat shock and hydrogen peroxide (Jenkins *et al.*, 1988; Lange & Hengge-Aronis, 1991b; McCann *et al.*, 1991). The feature is called cross protection. Development of the resistance depends on protein synthesis during first couple of hours of starvation (Jenkins *et al.*, 1988) and requires RpoS (Hengge-Aronis, 1993). Accordingly, *rpoS* mutants have decreased viability in stationary phase (Boaretti *et al.*, 2003; Lange & Hengge-Aronis, 1991b). The σ^S transcription factor is therefore the master regulator of an important stasis survival regulon which comprises of diverse set of proteins involved in central metabolism, stress response, cell morphology, mutation rates and virulence (Schellhorn, 2014). In addition, several global regulators, sigma factors (σ^{70} , σ^{FlhE} , σ^E and σ^{54}), flagellar master regulator FlhDC and small alarmones cAMP, (p)ppGpp, and c-di-GMP work in concert (Hengge, 2011).

A common theme in stationary phase survival is that cells fight with the accumulation of oxidative damage. Accordingly, omitting oxygen protects *E. coli* cells from losing viability during starvation (Dukan & Nystrom, 1998) and

rpoS mutants display elevated levels of oxidative damage (Dukan & Nystrom, 1998; Dukan & Nyström, 1999). Interestingly, some proteins are more susceptible than others (Dukan & Nystrom, 1998) and translational accuracy of the ribosome has been proposed to be responsible for some of the effects (Ballesteros *et al.*, 2001). Oxidative damage appears to be the bacterial counterpart of the free radical hypothesis of aging in case of higher organisms, accumulation of oxidative damage by reactive oxygen species produced by normal metabolism (Finkel & Holbrook, 2000).

Among oxidative damage, carbonylation is of special interest. Carbonylation happens to arginine, lysine, proline and threonine and appears to be irreversible, so that the only way to get rid of potentially damaged proteins is via degradation (Nyström, 2005). Furthermore, protein turnover, providing material for *de novo* protein synthesis in growth arrested cells, is suggested to be necessary for long term survival and development of general resistance to multiple stresses (Matin, 1991; Reeve *et al.*, 1984; Weichart *et al.*, 2003). Regardless of removal by degradation, accumulation of carbonylated proteins has been described in stationary phase *E. coli* (Desnues *et al.*, 2003).

After some time in stationary phase (about 1–2 days in LB, but longer in minimal media), during which the number of CFUs stays unaltered, the CFUs start to decline few orders of magnitude. This phase is called the death phase. Some of the phenomenon can be accounted for conversion of cells into viable but nonculturable state (VBNC, see below) – a fraction of the population loses the capability to form colonies on agar medium plates yet stays viable, as assessed by membrane potential, membrane integrity, and measures of intracellular enzymatic activity. Accordingly, VBNC cells have higher levels of irreversible oxidative damage, proteins are more carbonylated (Desnues *et al.*, 2003). Nevertheless, in some cells, eventually also in VBNC cells, respirations stops and cells lose membrane potential. Again, RpoS is important to enhance the growth resumption and prolong the VBNC duration before cell death (Boaretti *et al.*, 2003).

Long-term starvation conditions come with their own set of interesting phenomena, too numerous to cover here in detail and will therefore be just mentioned. First, the GASP phenotype – as stationary phase cell cultures are highly dynamic (Zambrano & Kolter, 1996), populations evolve, some that are so adapted to stationary phase that they take over the culture. Furthermore, genetic instability is induced by RpoS driven expression of error-prone DNA polymerases to increase the chances for useful mutations (Saint-Ruf & Matic, 2006). Second, there is VBNC mentioned above – cells lose the ability to form colonies, but remain viable and potentially able to restart growth (Oliver, 2005). Third, Lemonnier and colleagues described stationary phase contact-dependent inhibition (SCDI, (Lemonnier *et al.*, 2008), which manifests itself in emerging variants that appear to kill or inhibit the growth of parent strain. Although there are some similarities with GASP, the authors claim the processes to be functionally and genetically different.

1.1.3.3. Exit

After transfer to a new medium, composition of which is different from previous, cells do not necessarily start to grow and divide right away at the maximum speed supported by the new conditions. Instead, there is a certain period of delay during which the cells adjust to the new environment (Buchanan, 1918; Monod, 1949). This period is also called a lag phase. In comparison with exponential and stationary, way less is known about the lag phase despite its perceived importance to infection development and food safety.

Deceivably trivial, however, there are several definitions of the lag phase (Madar *et al.*, 2013) and even more ways to quantify it (Swinnen *et al.*, 2004). There are two main reasons for the multitude of definitions of what exactly comprises a lag phase. First, after transition to a new medium, cells initially grow bigger and only then, at some point, start to divide. This results in a period when turbidity of the culture increases, but the number of cells stays the same. Second, cells do not start to grow right away at maximal growth rate, there is an acceleration period. Note that before any indication of growth, regardless if defined by increase in mass or cell number, once the new substrate becomes available, starving cells respond with increased respiration and proteins synthesis almost instantaneously (Albertson *et al.*, 1990; Flardh & Kjelleberg, 1994). This fact makes use of some biochemical or molecular marker to define lag phase equally ambiguous.

The duration of the lag phase depends on the extent of the adjustments necessary to start the growth. Length of a lag phase is therefore in positive correlation with the length of a stationary phase (Albertson *et al.*, 1990; Amy *et al.*, 1983). This substantiates the suggestions that besides induction and/or activation of new enzymes at levels appropriate to new condition, some of the lag phase might account for repairing of the damage that has accumulated during stationary phase (Dukan & Nystrom, 1998; Dukan & Nyström, 1999).

Two specific and characteristic regulators of growth resumption are certainly worthy of note. First, RMF protein, responsible for ribosome dimerization (see chapter 1.1.3.1), facilitates faster growth resumption of *B. subtilis* (Akanuma *et al.*, 2016). Second, a small basic DNA-binding protein Fis regulates several processes important during growth resumption, *viz.* initiation of DNA replication (Filutowicz *et al.*, 1992), and transcription of rRNA (Nilsson *et al.*, 1990; Ross *et al.*, 1990). Further, *fis* expression – both mRNA and protein – is upregulated during growth resumption right before the number of cells starts to increase both in *Salmonella* and in *E. coli* (Ball *et al.*, 1992; Ninnemann *et al.*, 1992; Osuna *et al.*, 1995). Yet the knock-out mutant strains of *Salmonella* show relatively small (about +20 min per otherwise 120 min lag phase) delay in LB, absent in glucose minimal medium (Osuna *et al.*, 1995), and in *E. coli*, too, Fis protein appears dispensable for growth resumption (Rolfe *et al.*, 2012).

Regulation of lag phase correlates with the invasiveness of bacterial cells (Bättig *et al.*, 2006; Hathaway *et al.*, 2012) and affects antibiotic treatment of bacterial infections (Fridman *et al.*, 2014; Frimodt-Møller *et al.*, 1983). Most

bactericidal antimicrobials need some active target and thus are way less effective on non-growing bacteria, say, those of a lag phase. Indeed, wake-up kinetics determine the abundance of persister cells (Balaban *et al.*, 2004; Jöers *et al.*, 2010; Luidalepp *et al.*, 2011) – phenotypically different subset of parental population that is highly tolerant to antibiotic in question – which can result in failure of antibiotic treatment (Harms *et al.*, 2016; Lewis, 2007, 2010). Here, a cautionary note is appropriate – lag phase is just one facet of the persister phenomena, which probably is comprised of multiple heterogeneous states of bacterial physiology (Allison *et al.*, 2011b; Kaldalu *et al.*, 2016). We will briefly return to the issue of persisters in chapter 1.2.5.

1.2. The stringent response

In rapidly growing bacterial cells, proteins and stable RNA account for three fourths of the dry weight of the cell (Neidhardt & Umbarger, 1996) and, accordingly, about 70% of the cellular energy is devoted to translation (Russell & Cook, 1995). Thus, growth rate can be approximated by the concentration of ribosomes multiplied by the rate of peptide chain elongation (Dennis *et al.*, 2004). One would expect, therefore, that perturbations in translation machinery trigger a response that adjusts cell physiology to new conditions. Further, since production of ribosomes is controlled by the synthesis of rRNA (Paul *et al.*, 2004), one would expect the regulatory mechanism to affect most strongly the very process of rRNA transcription. That global response, indeed, is in place. It is termed the stringent response, adjustment program that, upon perturbations in environment, adjusts the physiology of the cell and results in a new, appropriate growth rate – including zero growth rate i.e. growth stop, if appropriate.

The stringent response is orchestrated by an accumulation of a nucleotide alarmones ppGpp and pppGpp, collectively (p)ppGpp. Acute accumulation of the alarmones re-allocates cellular resources away from rapid proliferation towards stress resistance and survival. The hallmark of the stringent response is, upon amino acid starvation, rapid curtailment of stable RNA synthesis (Paul *et al.*, 2004) and upregulation of amino acid biosynthesis (Traxler *et al.*, 2008). The wild-type strains are termed stringent and mutant strains that fail to do so, are called relaxed – the mutant cells continue to synthesize high levels of stable RNA when environmental conditions have become unfavorable for rapid growth, therefore, for rapid translation (see above). However, (p)ppGpp is a global regulator affecting all major synthetic activities of the cell: transcription, translation and replication. Moreover, (p)ppGpp exerts its regulatory role during unperturbed conditions, too.

As a result, stringent response has been implicated in virulence (Dalebroux *et al.*, 2010) and antibiotic survival (Doherty *et al.*, 2010; Harms *et al.*, 2016).

1.2.1. RelA

In many bacteria, upon sensing of uncharged tRNA in the ribosomal A-site (Haseltine & Block, 1973; Pedersen *et al.*, 1973), an adjustment program, termed stringent response, is activated (Stent & Brenner, 1961) (**Fig. 3**). Although uncharged tRNA binds the A-site with smaller affinity than charged tRNA (Rheinberger *et al.*, 1981; Schilling-Bartetzko *et al.*, 1992), the binding is facilitated by a drop in tRNA charging from 80–100% (Dittmar *et al.*, 2005; Ezekiel, 1964; Yegian *et al.*, 1966) to 5–40% during amino acid starvation (Böck *et al.*, 1966; Dittmar *et al.*, 2005; Ezekiel, 1964; Morris & DeMoss, 1965; Sørensen, 2001; Yegian *et al.*, 1966). Further, the transient interaction with the ribosome, in contrast to more permanent, is optimal for stringent response (Wendrich *et al.*, 2002).

In *E. coli*, the enzyme responsible for sensing uncharged tRNA in ribosomal A-site is RelA (Haseltine & Block, 1973), which, upon activation, catalyzes a pyrophosphoryl group transfer from ATP to 3' position of either GTP or GDP (Cochran & Byrne, 1974; Haseltine *et al.*, 1972; Haseltine & Block, 1973; Sy & Lipmann, 1973) resulting in pppGpp or ppGpp, respectively (**Fig. 3**). k_{cat} and K_m of RelA are similar for both GDP and GTP (Cochran & Byrne, 1974; Justesen *et al.*, 1986; Pedersen & Kjeldgaard, 1977). Given that the K_m is about 0.3–0.5 mM, i.e. higher than concentration of intracellular GDP and lower than GTP (Bochner & Ames, 1982; Buckstein *et al.*, 2008), it follows that pppGpp should be the main product. *In vivo*, during amino acid starvation, it is therefore mostly pppGpp that is synthesized (Fiil *et al.*, 1977; Weyer *et al.*, 1976). In most laboratory conditions studied, however, the pppGpp is rapidly hydrolyzed to ppGpp by an enzyme GppA (Somerville & Ahmed, 1979)(**Fig. 4A**). The only physiological difference known between the guanosine tetra- and pentaphosphate is quantitative, not qualitative, *viz.* ppGpp appears more potent in *E. coli* (Maciag *et al.*, 2010; Mechold *et al.*, 2013; Rymer *et al.*, 2012) (however, see also (Steinchen *et al.*, 2015)), therefore the two nucleotides are often considered together and collectively called (p)ppGpp.

Besides cognate uncharged tRNA in the ribosomal A-site, the synthesis activity of RelA needs, for yet to be determined reasons, ribosomal protein L11 (Friesen *et al.*, 1974; Parker *et al.*, 1976; Wendrich *et al.*, 2002). Finally, RelA synthetase activity is induced by alcohols, both *in vivo* (Mitchell & Lucas-Lenard, 1980) and *in vitro* (Sy *et al.*, 1973) Methanol stimulated activity of purified RelA without any ribosomes (Sy *et al.*, 1973) was the early indication that it is RelA and not the ribosome itself – for example, upon stimulation by RelA – that catalyzes the reaction of (p)ppGpp formation.




Figure 3. The defeat of the tRNA aminoacylation to keep up with the demand of protein synthesis triggers a regulatory adjustment process in bacteria called the stringent response. Amino acid starvation results in accumulation of uncharged tRNA which binds to the ribosomal A-site. Such ribosomes, with nonenzymatically bound uncharged cognate tRNA in A-site, are recognized by RelA protein. The C-terminal regulatory part of RelA binds to the ribosome and wraps around the tRNA establishing the tRNA in distorted shape as compared to enzymatically accommodated A-site tRNA, whereas the N-terminal part of RelA synthesizes (p)ppGpp from ATP and GTP or GDP. It is still open to dispute whether most of the (p)ppGpp synthesis takes part while RelA is still bound on the ribosome or off the ribosome. Nonetheless, (p)ppGpp acts as a global and pleiotropic regulator which ultimately results in the restoration of aminoacylation of tRNAs. Once again charged, cognate tRNAs are delivered to the ribosome the usual enzymatic way by EF-Tu and replace the weakly bound uncharged tRNA in A-site. Note that it results also concomitant release of the E-site bound tRNA.

The structure of RelA bound to the ribosome reveals a highly distorted tRNA (Agirrezabala *et al.*, 2013; Arenz *et al.*, 2016; Brown *et al.*, 2016) with the C-terminal part of RelA buried deep into the ribosome and wrapped around tRNA (**Fig 3**). Since the N-terminal part of RelA has catalytic functions (Schreiber *et al.*, 1991; Svitil *et al.*, 1993) and the C-terminal part has regulatory functions (Gropp *et al.*, 2001; Schreiber *et al.*, 1991; Svitil *et al.*, 1993; Yang & Ishiguro, 2001a), it has been proposed that embedding of C-terminus facilitates the active conformation of RelA (Arenz *et al.*, 2016). Regardless of embedding, interference with regulation by tagging the C-terminus might still account for some of the controversies in reports. Earlier biochemical studies, with native RelA, suggested that RelA stays on the ribosome (Richter, 1976). Then, working *in vitro* with C-terminal histidine tagged RelA, it was suggested that RelA comes off from the ribosome upon activation (Wendrich *et al.*, 2002). In addition, it was speculated that RelA binds back quickly, “hops” from ribosome to ribosome – inferred from the fact that (p)ppGpp synthesis of RelA was six times faster when ribosomes were in vast excess (10-fold). The following *in vivo* single-molecule tracking study, using C-terminal fluorescent label, supported the view of RelA being active off the ribosome, however, it argued against hopping (English *et al.*, 2011). However, next *in vivo* single molecule study, this time comparing couple of fluorescent labels in C-terminus and having longer linkers between the label and RelA, suggested that RelA is off the ribosome in

unstressed conditions, amino acid starvation induces binding to the ribosome and (p)ppGpp is synthesized while RelA is bound to the ribosome (Li *et al.*, 2016).

The molecular model of binding and activity, when finally solved, must take into account a couple of things. First, there are way more ribosomes than RelA molecules in the *E. coli* cell (one molecule per 200 ribosomes (Pedersen & Kjeldgaard, 1977)). Second, it should account for at least some of the (p)ppGpp-independent effects of starvation. For example, protein synthesis is inhibited already by low level accumulation of uncharged tRNA long before RelA is stimulated (Rojiani *et al.*, 1989, 1990). Third, RelA is somehow regulated by oligomerization (Gropp *et al.*, 2001; Yang & Ishiguro, 2001a), possibly by forming dimers (Yang & Ishiguro, 2001b), and feedback-stimulated by its product (Shyp *et al.*, 2012), although, inhibited at yet higher (p)ppGpp levels (Beljantseva *et al.*, 2017a). Finally, it might be crucial to include the role of toxin-antitoxin systems in the model (Christensen & Gerdes, 2004; Diderichsen *et al.*, 1977; Maisonneuve *et al.*, 2013; Tian *et al.*, 2016).

When does a bacterial cell have to deal with a lot of uncharged tRNA? In laboratory conditions, stringent response is elicited by either (i) reducing the availability of amino acids or (ii) reducing the aminoacylation of tRNA. In addition to uncharged tRNA, cell wall driven regulation of RelA activity has also been proposed (Kusser & Ishiguro, 1987). Finally, (p)ppGpp accumulation is induced by heat shock (Braedt & Gallant, 1977; Lemaux *et al.*, 1978; Lund & Kjeldgaard, 1972), though how exactly and to what extent is RelA activated, is yet unclear. In unperturbed conditions and during slow transitions, in fact, (p)ppGpp has a role too, probably it is fine tuning the bacterial physiology in accordance with growth potential of the environment. Accordingly, in exponentially growing *E. coli* cells with disruption of the RelA function, (p)ppGpp is still present (although at about 3-fold lower levels) (Gallant *et al.*, 1970) – most of the (p)ppGpp in unperturbed conditions originates from yet another enzyme, SpoT which will be portrayed in the next chapter.

1.2.2. SpoT

Early studies with mostly non functional (p)ppGpp synthetase version of RelA (encoded by a *relA1*, an allele that has an amino terminal IS2 insertion (Metzger *et al.*, 1989) and is wide-spread among laboratory strains of *E. coli*) suggested that there must be an alternative, perhaps a weaker, source of (p)ppGpp synthesis activity (Atherly, 1979; Friesen *et al.*, 1978). Indeed, in *E. coli* and in other gamma-proteobacteria, (p)ppGpp can also be synthesized by a homologous protein, SpoT (Laffler & Gallant, 1974; Stamminger & Lazzarini, 1974). *E. coli* strains devoid of both RelA and SpoT lack ppGpp altogether, a phenotype designated (p)ppGpp⁰, which renders cells to severe multiple amino acid auxotrophy (Xiao *et al.*, 1991).

SpoT synthetase activity is triggered in response to starvations of various nature: carbon (Lazzarini *et al.*, 1971), iron (Vinella *et al.*, 2005), fatty-acid (Seyfzadeh *et al.*, 1993), and phosphate (Lazzarini *et al.*, 1971; Spira *et al.*, 1995) (**Fig. 4A**). In addition, osmotic (Harshman & Yamazaki, 1972) and heat shock (Gallant *et al.*, 1977) induce the (p)ppGpp synthesis activity of SpoT. In good accordance with the more moderate nature, SpoT is responsible for maintaining the ppGpp levels during steady-state growth conditions (Murray & Bremer, 1996; Ryals *et al.*, 1982).

Besides weak synthesis activity, SpoT also hydrolyses (p)ppGpp and is responsible for the main (p)ppGpp degradation activity in the cell (An *et al.*, 1979; Heinemeyer *et al.*, 1978; Heinemeyer & Richter, 1978). In wild-type *relA* background, therefore, *spoT* appears essential (Xiao *et al.*, 1991) – since high (p)ppGpp levels stop the cell growth (see chapter 1.2.4), most simple explanation is that one just does not reap *relA*⁺ *spoT*⁻ cells, they do not grow. Experimental validation to that claim, i.e. by *spoT* knock-down, has not been reported. The hydrolysis domain of SpoT consists of conserved His-Asp (HD) residues (Aravind & Koonin, 1998) and requires Mn²⁺ for the activity (Johnson *et al.*, 1979; Sy, 1977).




Figure 4. (p)ppGpp has a role beyond the amino acid starvation and family of proteins responsible for its metabolism. (A) In *E. coli*, in addition to the RelA, there is a homologous protein SpoT that is responsible for both (p)ppGpp production (pink) and hydrolysis (green). At least for RelA, specificity constants for GTP and GDP are similar, yet there is about seven GTP molecules per one GDP in exponentially growing bacterial cells, therefore, mostly likely pppGpp is the major product. pppGpp, nonetheless, is rapidly turned into ppGpp by GppA. While synthesis activity of RelA is triggered by amino acid starvation, SpoT is regulated by various environmental cues, net outcome of which is determined by the balance between its hydrolysis and synthesis activities. Note that RelA and SpoT are very similar, so that former has also (p)ppGpp hydrolysis domain albeit inactive. **(B)** In contrast to RelA (strong synthetase, thick pink arrow) and SpoT (weak synthetase, thin pink arrow; strong hydrolase, thick green arrow) which are common only in beta- and gamma-proteobacteria, most of the bacterial species contain but one homologous bifunctional protein (with fairly strong activity of (p)ppGpp synthesis and hydrolysis). Furthermore, many of the bacteria have accessory small proteins, with only synthetase or hydrolase domain.

Regulation of the SpoT activities is complex and only some of the interaction partners of SpoT have been elucidated. A GTPase Obg (also called ObgE, YhbZ or CgtA) seems to inhibit the (p)ppGpp synthesis activity of SpoT in rapid growth conditions (Jiang *et al.*, 2007; Raskin *et al.*, 2007; Wout *et al.*, 2004). In addition, acyl carrier protein (ACP) stimulates SpoT-dependent (p)ppGpp accumulation during fatty acid starvation (Battesti & Bouveret, 2006).

Regardless of the interaction partners, the balance between (p)ppGpp hydrolysis and synthesis activities is the key mechanism for adjustment of (p)ppGpp levels by SpoT (Gallant *et al.*, 1972; Murray & Bremer, 1996). For example, during carbon source shift-down, both ppGpp synthesis and degradation are inhibited, but the degradation is reduced to greater extent giving the net expansion of (p)ppGpp pool (Friesen *et al.*, 1975; Murray & Bremer, 1996). In case of single amino acid starvation, both activities are again inhibited, but the synthesis is inhibited more (accumulation of uncharged tRNA inhibits degradation (An *et al.*, 1979; Richter, 1980), however, since overall (p)ppGpp levels drop in amino acid starved *relA* mutants (Ryals *et al.*, 1982), it can be deduced that synthesis is inhibited to greater extent). In contrast, during multiple amino acid starvation, the synthesis is stimulated and degradation inhibited (Murray & Bremer, 1996).

The wide variety of environmental inputs that result in the regulation of SpoT has been perplexing. Complicating the studies, extracts of *E. coli* have no SpoT dependent synthetase activity (Heinemeyer & Richter, 1977). In an attempt to explain most of the observed phenomena, the following model has been proposed (Bremer & Dennis, 2008; Dennis *et al.*, 2004; Ehrenberg & Kurland, 1984). SpoT monitors the functioning of the ribosome so that its synthetase activity is stimulated whenever the peptide chain elongation rate is sub-optimal – due to molecular crowding or decreased charging of several tRNAs (see chapter 1.2.4). There is, however, an additional constraint – SpoT synthetase activity is unstable (Murray & Bremer, 1996), it requires protein synthesis and thus disappears when protein synthesis stops altogether. The model definitely has its appeal as it is capable to adjust other sensory inputs and interaction partners (*viz.* Obg, ACP, see above), *i.e.* is open to refinement in details, yet explains a wide variety of observations.

1.2.3. The rest of the RelA/SpoT family

Sequence analysis reveals that combination of RelA and SpoT has very limited phylogenetic distribution – they are present only in among beta- and gamma-proteobacteria (Atkinson *et al.*, 2011). In the majority of bacterial species, there is but one full-length protein, with both synthetase and hydrolase activity, termed Rel, *viz.* Rel_{Bsu} or Rel_{Mtb} for the one of *B. subtilis* and *Mycobacterium tuberculosis*, respectively (**Fig. 4B**). In addition, in many species, the (p)ppGpp levels are regulated by small alarmone synthetase (SAS), which contain only of (p)ppGpp synthetase domain, and small alarmone hydrolases (SAH), which

contain only hydrolase domain (**Fig. 4B**). Not much is known about bacterial SAHs, however, SASs have been studied in *B. subtilis* (Nanamiya *et al.*, 2008; Steinchen *et al.*, 2015), *Enterococcus faecalis* (Abranches *et al.*, 2009; Beljantseva *et al.*, 2017b; Gaca *et al.*, 2015), *Streptococcus mutans* (Lemos *et al.*, 2007), and *Vibrio cholerae* (Das *et al.*, 2009).

Similarly to RelA, (p)ppGpp synthesis activity of Rel is activated in response to amino acid starvation in some bacterial species including *E. faecalis* (Gaca *et al.*, 2012), *Streptomyces coelicolor* (Martínez-Costa *et al.*, 1998; Strauch *et al.*, 1991), and *Myxococcus xanthus* (Harris *et al.*, 1998). In *M. tuberculosis*, Rel_{Mtb} synthetase is regulated by its product (Syal *et al.*, 2015), activated by uncharged tRNA in ribosomal A-site (Avarbock *et al.*, 2000), however, *in vivo* experiments with amino acid starvation failed to induce (p)ppGpp accumulation, instead, removal of all nutrients was necessary (Primm *et al.*, 2000). Regardless of the reasons for the discrepancy, examples of species that do not produce (p)ppGpp upon amino acid starvation are well documented and include *Rhodobacter sphaeroides* (Acosta & Lueking, 1987; Eccleston & Gray, 1973), *Rhizobium meliloti* strain 41 (Belitsky & Kari, 1982), *Rhizobium tropici*, *Azobacter vinelandii*, *Azomonas agilis* (Howorth & England, 1999). Some of the species are still stringent, *R. meliloti* 41 and *R. sphaeroides* restrict stable RNA synthesis upon amino acid starvation, yet do it without the involvement of (p)ppGpp (Acosta & Lueking, 1987; Belitsky & Kari, 1982; Eccleston & Gray, 1973). Furthermore, they do produce (p)ppGpp, *R. meliloti* 41 in carbon and ammonium deprivation (Belitsky & Kari, 1982), and *R. sphaeroides*, photosynthetic bacterium, upon decrease in light intensity (Eccleston & Gray, 1973).

In *Caulobacter crescentus* (Chiaverotti *et al.*, 1981) and *Helicobacter pylori* (Scoarughi *et al.*, 1999) the amino acid starvation does not trigger (p)ppGpp synthesis nor reduction in stable RNA transcription. Again, however, those species are able to synthesize (p)ppGpp. In *C. crescentus*, (p)ppGpp is accumulating in response to starvation for carbon or nitrogen but not for phosphate (Boutte & Crosson, 2011; Chiaverotti *et al.*, 1981; Lesley & Shapiro, 2008; Ronneau *et al.*, 2016). Interestingly, although the synthetase activity was indifferent to amino acid starvation, the functioning of ribosomes was still important for the control of the activity of Rel_{Cc}, aligning well with the proposed role of SpoT in governance of translational machinery (see chapter 1.2.2). In *H. pylori*, (p)ppGpp accumulates in response to carbon and serum starvation and acid stress (Wells & Gaynor, 2006; Zhou *et al.*, 2008). Both bacteria are able to restrict stable RNA synthesis when (p)ppGpp is synthesized (Amemiya, 1991; Wells & Gaynor, 2006).

Given the differences in stresses that trigger stringent response in various bacteria, be it assessed by stable RNA curtailment on (p)ppGpp accumulation, it has been proposed that these follow the adaptations to particular lifestyles of each species (Boutte & Crosson, 2013).

1.2.4. (p)ppGpp in growth and survival

Growth rate control is a term used to describe the systematic variation of bacterial cell composition at different growth rates, most remarkably described by seminal work of Schaechter *et al.* (Schaechter *et al.*, 1958): given the balanced growth, there is exponentially more RNA, DNA and cell mass per cell at higher growth rates (see chapter 1.1.2). This entails that the synthesis rates, per cell, are higher (see chapter 1.1.1). The largest difference is for RNA, followed by cell mass and DNA. When cells are shifted from low to high growth rate, or vice versa, per cell, the RNA and protein production are regulated first, while DNA synthesis and the speed of cell division follow later (Brunschede *et al.*, 1977; Kjeldgaard *et al.*, 1958).

Growth rate and (p)ppGpp levels are inversely correlated, e.g. slowly growing cells have higher (p)ppGpp levels (Ryals *et al.*, 1982). Higher (p)ppGpp levels result in lower amounts of stable RNA synthesis and this reduction in translation apparatus results in slower growth (amount of ribosomes \times amino acid synthesis rate \sim growth rate; see introduction to chapter 1.2). However as trivial as it might seem, there are couple of complications to establish such a simple causal relationship. First, transitions, necessary to alter (p)ppGpp levels, will have profound secondary effects on cellular metabolism in itself. To that end, studies with inducible expression of (p)ppGpp synthesis without any starvation (Rodionov & Ishiguro, 1995; Schreiber *et al.*, 1991; Svitil *et al.*, 1993) and experiments with ppGpp⁰ strain are instrumental. Note that the ppGpp⁰ strains are genetically unstable, however, expert advice for working with them can be found from the literature (Potrykus *et al.*, 2010). Second, regulation at transcription level, the hallmark of stringent response, can not act quickly. This implies that other processes – toxin-antitoxin systems (Harms *et al.*, 2016), trans-translation (Christensen & Gerdes, 2003, 2004; Li *et al.*, 2008), to name a few – are integral part of the regulation and will introduce other inputs. Third, direct and indirect effects of (p)ppGpp are very likely to act simultaneously.

Much of the growth rate control by (p)ppGpp can be explained by assuming that the translational speed of ribosome, although it can vary two-fold (Bremer & Dennis, 1996), is kept close to maximal possible. Therefore, the major mode to increase the production of protein at higher growth rates is to increase the amount of ribosomes. When the speed of ribosome becomes suboptimal, probably detected by SpoT (see chapter 1.2.2), (p)ppGpp starts to curtail the amount of stable RNA therefore reducing the abundance of translational machinery (Bremer & Dennis, 2008; Dennis *et al.*, 2004; Ehrenberg & Kurland, 1984). Some recent analysis has suggested that molecular crowding might be a major factor that limits the maximum speed of translation making it to deviate from constant speed at all times (Klumpp *et al.*, 2013).

During severe starvation, when the zero growth rate is appropriate, besides the curtailment of activities required for rapid proliferation, (p)ppGpp induces the increase in σ^S levels (Gentry *et al.*, 1993), transcription of the ribosome dimerization factors *rmf* (Izutsu *et al.*, 2001), downregulation of the *fis*

promoter (Ninnemann *et al.*, 1992). Also osmoprotectants and/or storage compounds, such as glycogen and polyphosphate, accumulate (Rao & Kornberg, 1996; Wei *et al.*, 2000), both being upregulated by (p)ppGpp (Kuroda *et al.*, 1997; Rao *et al.*, 1998). Polyphosphate, however, has an additional role in activation of toxin-antitoxin systems (Maisonneuve *et al.*, 2013), which are connected to stringent response very intimately (Harms *et al.*, 2016). All these and numerous other factors are important for stasis survival and the outgrowth following (see chapter 1). Accordingly, (p)ppGpp has been reported important for stasis survival in *H. pylori* (Mouery *et al.*, 2006), *C. crescentus* (Lesley & Shapiro, 2008), *M. tuberculosis* (Dahl *et al.*, 2003; Primm *et al.*, 2000), *Borrelia burgdorferi* (Drecktrah *et al.*, 2015), *Legionella pneumophila* (Trigui *et al.*, 2014), and *Campylobacter jejuni* (Gaynor *et al.*, 2005).

1.2.5. (p)ppGpp in virulence

Given the general themes of stringent response – dormancy and endurance – and the global nature of the (p)ppGpp elicited changes in bacterial physiology, it does not perhaps come as a surprise that the alarmone has implications for virulence. The importance of (p)ppGpp for invasion and survival during infection has been indicated for numerous bacterial species. Attenuated infection in mice, for stringent response defective strains, has been reported for *M. tuberculosis* (Dahl *et al.*, 2003; Stallings *et al.*, 2009), *V. cholerae* (Silva & Benitez, 2006), *S. typhimurium* (Webb *et al.*, 1999), *Yersinia pestis* (Sun *et al.*, 2009), *Streptococcus pneumoniae* (Hava & Camilli, 2002; Kazmierczak *et al.*, 2009), and *Brucella* sp. (Dozot *et al.*, 2006).

One of the reoccurring principles – in studies where stringent response is implicated in virulence – is that of a dormant, stationary phase like phenotype (Boes *et al.*, 2008; Song *et al.*, 2004; Webb *et al.*, 1999). This leads us to one of the most controversial and peculiar connection between stringent response and virulence – the persister cell. An interested reader should consult numerous excellent recent reviews on the topic (Amato *et al.*, 2014; Balaban, 2011; Brauner *et al.*, 2016; Cohen *et al.*, 2013; Harms *et al.*, 2016; Kaldalu *et al.*, 2016; Lewis, 2010; Maisonneuve & Gerdes, 2014), which is way too broad and complex to be discussed in its entirety here. Instead, only few carefully selected issues pertinent to current study will be discussed next.

Already at the earliest days of antibiotic usage, Bigger noticed that bactericidal antibiotics cannot be used for sterilization purposes and called the survivors persisters (Bigger, 1944). Turns out that in growing bacterial population, one which is susceptible to certain bactericidal antibiotic, there are always some cells that are not killed and resume growth once antibiotic treatment is discontinued (Balaban *et al.*, 2004; Jöers *et al.*, 2010; Roostalu *et al.*, 2008). Given the fact that persisters form exactly similar, mostly susceptible culture once the antibiotic has been removed (Bigger, 1944; Keren *et al.*, 2004a), verifies that the cells are not mutants but phenotypic variants, a form of phenotypic hetero-

geneity. In contrast to resistant bacteria, in the presence of antibiotic, persisters are not growing but survive. There is subtle yet important difference between non-growing and persister cells. In growth-supporting environment, the persister cells belong to the subpopulation that is non-replicating and can thus survive, for example, ampicillin treatment. Importantly, however, not every non-growing cell is persister, in fact, only a tiny fraction of these non-growing and not killed cells might be able to resume growth and form colonies (less than 1% in some conditions (Roostalu *et al.*, 2008)) as required by the definition of persisters.

In principle, once the antibiotic treatment is discontinued, persisters can be the source of recurrent infection. This has put forth in a lot of studies, theoretical and experimental, to elucidate the mechanism, meaning and ways to kill persister cell. A large body of work on persister cells, however, has been performed in laboratory conditions, using batch culture. Yet in infection sites, non-growing persister cells could be imagined to be cleared off by the host's immune system. Furthermore, not all antibiotics are bactericidal – some are bacteriostatic, but still work, in concert with immune system. Importantly therefore, in recent years, there is a slowly accumulating body of evidence that persistence phenomenon does indeed have some role in real infection – persister level appears to increase during the course of antimicrobial therapy in case of *E. coli* (Schumacher *et al.*, 2015), *P. aeruginosa* (Mulcahy *et al.*, 2010), *M. tuberculosis* (Torrey *et al.*, 2016), or *Candida albicans* (Lafleur *et al.*, 2010), a yeast.

A diverse set of physiological states are probably responsible why some cells of certain bacterial species in specific conditions survive particular antibiotic treatment (Kaldalu *et al.*, 2016), accordingly, persister cell formation pathways are numerous (Hansen *et al.*, 2008; Torrey *et al.*, 2016). Nevertheless, toxin-antitoxins pairs – capable of interfering with essential cellular processes and thereby inhibiting bacterial growth – are likely involved, it is yet another question if stringent response happens before, after or throughout the induction of toxins (Aizenman *et al.*, 1996; Cheverton *et al.*, 2016; Christensen & Gerdes, 2004; Germain *et al.*, 2015; Kaspary *et al.*, 2013; Keren *et al.*, 2004b; Maisonneuve *et al.*, 2013). Finally, (p)ppGpp has been suggested to orchestrate cell wall modulation to protect from β -lactam antibiotics (Goodell & Tomasz, 1980; Kusser & Ishiguro, 1985; Pisabarro *et al.*, 1990; Rodionov & Ishiguro, 1995; Vanderwel & Ishiguro, 1984).

AIMS OF THE STUDY

We set out to study the relationship between the growth state, intracellular (p)ppGpp levels and the outcomes of antibiotic treatment. The experimental part thus consists of three linked studies with following objectives:

- Ref. I** To study the relationship between growing, non-growing bacterial cells, antibiotic susceptibility and innate immune system.

- Ref. II** Since the non-growing state in growth supporting environment was protective against both antibiotic treatment and action of the immune system (Ref. I), we set out to elucidate mechanisms controlling the growth resumption.

- Ref. III** As the stringent response emerged as a key player in growth resuscitation (Ref. II) and given its reported importance to bacterial virulence, we set up a high-throughput search for inhibitors of the stringent response.

2. RESULTS AND DISCUSSION

2.1. Relationship between bacterial growth, action of antibiotic and innate immunity (I)

It is known that after antibiotic treatment, urinary tract infections by uropathogenic *E. coli* (UPEC) can reoccur caused by the very same strain (Russo *et al.*, 1995). The involvement of phenotypic heterogeneity, i.e. persister cell formation has been suggested as a mechanism behind the survival of bactericidal antibiotic treatment and recurrent infection (Harms *et al.*, 2016). In addition to antibiotic treatment, however, surviving bacterial cells have to endure the insult of immune system. Yet the connection between bacterial physiology and immune system remains largely uncharted. We therefore set out to investigate if heterogeneity of bacterial culture affects survival of the killing by immune system and how does the simultaneous antibiotic treatment affect the eradication of bacteria. To that end, we used (i) UPEC strain CFT073 (O6:K2:H1) (Mobley *et al.*, 1990; Welch *et al.*, 2002), isolated from a patient with acute pyelonephritis i.e. a strain capable of causing bacteremia, and (ii) human serum as a model for innate immunity.

First, bacterial cells were treated with human serum (at 50% final concentration) and course of the treatment was followed by sampling, plating and counting CFUs. A subpopulation of bacterial cells turned out to be tolerant to the complement system of human serum (I, Fig. 1). In addition, as we used stationary phase cells to start the experiment, it was evident that killing by serum coincides with the time of growth resumption (I, Fig. 1) suggesting that the lag phase CFT073 cells are refractory to complement killing. However, when exponentially growing culture was stopped by addition of chloramphenicol, the cells were still efficiently killed by serum (I, Fig. 6B) warranting the caution to be executed when interpreting results merely based on dualistic growth no-growth axis – just as growing cells, non-growing cells do not necessarily have to be alike.

Next, we factored in the antibiotic treatment using bactericidal antibiotics from different classes – cell wall targeting ampicillin, the DNA replication inhibiting norfloxacin, and the translation inhibiting amikacin. These antibiotics are often used to study persisters and persistent infections (Allison *et al.*, 2011a; Balaban *et al.*, 2004; Bigger, 1944; Keren *et al.*, 2004b; Moyed & Bertrand, 1983). None of the antibiotics killed non-growing CFT073 cells even if added at several times the MIC (resuscitated in PBS) (I, Fig. 2; SFig 3A and 3B). Adding ampicillin to the serum around at its MIC (2 $\mu\text{g/ml}$) reduced the number of surviving cells about an order of magnitude suggesting that some cells, not killed by serum, could be killed by ampicillin (I, Fig. 2A). In case of norfloxacin, around its MIC (0.125 $\mu\text{g/ml}$), the number of cells killed by serum alone compared to simultaneous treatment with antibiotic were identical (I, Fig. 2B), suggesting – but not establishing – a possible overlap between cells killed by

norfloxacin and human complement system. Finally, adding amikacin to the serum around its MIC (8 $\mu\text{g/ml}$) and higher, decreased the number of survivors by 1–2 orders of magnitude (I, Fig. 2C), suggesting that some cells, not killed by serum, could be killed by amikacin. Interestingly, both active and heat-inactivated serum seemed to promote killing at lower amikacin concentrations (sub-MIC, < 8 $\mu\text{g/ml}$)(I, Fig. 2C). The reasons for that serum-promoted sub-MIC killing still await discovery. Finally, note that for all the antibiotics at concentrations of several times the MIC, it was the antibiotic that determined the outcome of the treatment, serum complement system did not add eradication efficiency to the antibiotic (I, Fig. 2A-C).

To interrogate the possible impact of population heterogeneity on serum mediated killing, we investigated the effect of growth in further detail. We used a previously established IPTG inducible GFP reporter system (Roostalu *et al.*, 2008) that allowed us to study cell division and growth resumption at the single cell level. We found that three classes of bacterial cells could be distinguished. Importantly, they all were equally well detected by complement system (based on the opsonization) (I Fig.5). Yet only the most rapidly proliferating and the dormant cells were protected from the action of serum whereas majority of the cells, belonging to the group of intermediate growth rate, were susceptible to serum (I, Fig. 3). In case of the simultaneous application of antibiotic treatment and serum incubation, only the dormant cells were surviving – the rapidly growing cells were efficiently eradicated by the action of antibiotics of different classes (I, Fig. 4). Note that norfloxacin and amikacin seemed to inhibit the growth resumption (I, Fig. 4A and 4C) and, as CFUs revealed, latter was actually pretty effective in killing the dormant cells in growth supporting environment (I, Fig. 4B and 4D). In contrast, amikacin was not killing bacterial cultures in environments not supporting growth (I, SFig 3A), reminding thus, again, that non-growing cells are not necessarily alike.

In summary, human serum complement mediated killing eradicates most of the growing population of UPEC strain CFT073, only the very rapidly growing and the dormant cells survive the insult. During simultaneous application of serum and various antibiotics from different classes, however, only dormant cells survive as antibiotics result in clearance of the rapidly growing cells. The reasons why bacterial cells are recognized uniformly by complement yet not killed, remains to be elucidated.

2.2. The role of stringent response in growth resumption (II)

Adjustments of the length and physiology of the lag phase are involved in antibiotic tolerance and persistence (Balaban *et al.*, 2004; Fridman *et al.*, 2014; Jøers *et al.*, 2010; Luidalepp *et al.*, 2011). As we had established that killing by the complement system correlates with the growth resumption of UPEC, i.e. the

lag phase cells were not killed by serum (I, Fig. 1), we next set out to investigate potential genes involved in growth resumption of *E. coli*. Of several target genes initially studied, we eventually focused on the stringent response factor RelA. Notably, the very field of stringent response research was once initiated by isolation of mutants unable to resume growth after amino acid starvation (Alföldi *et al.*, 1963; Diderichsen *et al.*, 1977; Fiil & Friesen, 1968; Raskó & Alföldi, 1971).

We constructed the *relA* deletion strain of *E. coli* K-12 lineage (BW25113), and tested the ability of the relaxed cells to resume growth after being some time in stationary phase. There was no difference between wild-type and $\Delta relA$ culture when resuscitated in undefined rich medium (LB) (II, Fig. 1A). The relaxed culture, however, showed about four hour growth resumption delay when diluted into fresh defined minimal medium (M9 with 0.4% glucose) (II, Fig. 1B and Table 1). Since turbidity of the culture (II, Fig. 1) and number of CFUs (II, SFig 2) were in good agreement, $\Delta relA$ cells are not losing viability in the stationary phase. It is still possible, however, that there is enhanced accumulation of damage in $\Delta relA$ cells, therefore it takes more time for the to recover. Indeed, increased level of mistranslation has been described in relaxed cells (O'Farrell, 1978; Wagner & Kurland, 1980) although the role of (p)ppGpp in it seems to be indirect – (p)ppGpp induces translational pausing, this results in lower abundance of mRNA due to enhanced decay. Limited protein synthesis, in turn, increases the charging of tRNAs, together with lower abundance of mRNA, hungry codons are encountered less frequently and, therefore, translational fidelity increases (Sørensen *et al.*, 1994; Wagner & Kurland, 1980).

The stringent response is induced during shiftdowns in growth environment including transition to stationary phase (Lazzarini *et al.*, 1971). Thus, it is somewhat surprising that the regrowth delay was determined by the regrowth medium instead of the medium where $\Delta relA$ cells were growing from exponential into stationary phase (II, Fig. 1C and 1D). Note that this does not rule out explanation that inappropriate entry into stationary and/or accumulated damage during the phase (see the above paragraph) are the reasons behind the observed phenotype. Nonetheless, to begin with, we next focused exclusively on growth resumption conditions.

Primarily, we considered two major differences between the undefined rich (LB) and glucose minimal medium: (i) LB contains amino acids and (ii) supports faster growth rate. The first aspect seemed relevant given the central importance of (p)ppGpp for regulation of amino acid anabolism (Paul *et al.*, 2005; Tedin & Norel, 2001; Traxler *et al.*, 2008). As for second aspect – given that (p)ppGpp levels and growth rate are inversely correlated (Potrykus *et al.*, 2010; Ryals *et al.*, 1982) and, in exponential phase, (p)ppGpp levels are lower in $\Delta relA$ compared to wild-type cells (Gallant *et al.*, 1970), (Potrykus *et al.*, 2010; Ryals *et al.*, 1982) relaxed cells might therefore be primed for growth in environments supporting rapid proliferation, but fail to do so in slower growth conditions. Following experiments revealed that a full set of natural amino acids, when supplemented to minimal glucose medium, could indeed abolish

the growth resumption delay of $\Delta relA$ culture (II, Fig. 2B). In order to examine the second aspect, we supplied the amino acids, but decreased the growth rate support by changing to poorer carbon source, switched from glucose to glycerol. Again, $\Delta relA$ cells resumed growth equally to wild-type (II, SFig. 3) suggesting that growth speed might be irrelevant and what matters is the lack of or presence of amino acids. Thus, we made an effort to find out if $\Delta relA$ cells were deprived of some certain single amino acid. To that end, we supplied (II, Fig. 3D-E) or omitted (II, Fig. 3A-C) just one out of 20 natural amino acids to the growth resumption medium. However, both approaches were perturbing the growth resumption of just the wild-type (II, Fig. 3A and 3D). Notably, most of the effects were absent when same conditions were applied to exponential phase cells (II, Fig. 4). Overall, we could establish that, among other effects, probably the ones caused by aspartate-pyruvate family of amino acids (Aspartate family: aspartate, asparagine, methionine, threonine, and lysine; Pyruvate family: alanine, valine, leucine, and isoleucine) were most prevalent. Simplest speculation is, since these amino acids are among the most abundant ones in the cell (Bogatyeva *et al.*, 2006; Okayasu *et al.*, 1997) (furthermore, as synthesized very closely related pathways, collectively very abundant), the cells might suffer from the lack these amino acids the first/strongest during starvation. One could also argue that those amino acids stand out due to (p)ppGpp involvement in regulation of branched-chain amino acid biosynthesis (Tedin & Norel, 2001; Traxler *et al.*, 2008). The issue is definitely open to further studies.

There is an earlier work on *Vibrio* sp. strain 14 suggesting the role of amino acid starvation in growth resumption (Flardh & Kjelleberg, 1994). The authors found that during growth resumption, protein synthesis is initiated fast yet without much of an amino acid biosynthesis (Flardh & Kjelleberg, 1994). This leads into amino acid starvation which triggers stringent response necessary to initiate transcription of genes of amino acid biosynthesis. Importantly, control of rRNA synthesis is relaxed immediately after reversal of starvation i.e. if upshift is coupled to amino acid deprivation, rRNA synthesis is not curtailed (Jacobson & Gillespie, 1968; Nakada & Marquisee, 1965). The reason for this temporary relaxed phenotype awaits elucidation, but together with the body work done in Gourse's lab (i.e. (Murray *et al.*, 2003)) a following picture emerges: early in growth resumption, initiating nucleotide is the main regulator of rRNA transcription, (p)ppGpp becomes important later and reacts to shiftdowns.

While interrogating the role of amino acids and/or growth rate in growth resumption, we made a serendipitous discovery that glycerol itself allowed the $\Delta relA$ to resume growth as fast as wild-type (II, Fig. 5B). The reasons for that are far from clear, however, some connections between the nature of carbon source and stringent response are well known. Most notably, stringent response is involved in regulation of glycogen accumulation together with carbon storage regulator (*csr*) network (Edwards *et al.*, 2011; Romeo & Preiss, 1989). When growing on glucose, for example, *relA* gene is required for glycogen accumulation upon amino acid starvation, however, when glycerol is the carbon source, high cellular levels of cyclic AMP can replace the requirement for RelA (Leckie

et al., 1980; Taguchi *et al.*, 1980). Relatedly, (p)ppGpp regulates negatively cAMP response protein (CRP) (Johansson *et al.*, 2000). Moreover, cAMP, (p)ppGpp and CRP are all involved in regulation of the branched-chain amino acid biosynthesis (Freundlich, 1977). Finally, the activity of SpoT also governs the usage of carbon source, monitors the energetic status of the cell (Harshman & Yamazaki, 1971; Lazzarini *et al.*, 1971; Murray & Bremer, 1996) and can thus be involved in growth resumption phenomena we have observed.

Finally, we studied the role of the delayed growth resumption of $\Delta relA$ strain in susceptibility to bactericidal antibiotic treatment. Indeed, $\Delta relA$ cells were better protected from ampicillin treatment during regrowth on glucose (II, Fig. 5C). Surprisingly, though the $\Delta relA$ cells resumed growth on glycerol similarly to wild-type (II, Fig. 5B), they were still better at surviving ampicillin treatment (II, Fig. 5D). This warrants the notion that study of bacterial physiology starts from inspection of growth rate, but should not end there (see also chapter 2.1).

2.3. A quest for a stringent response inhibitor (III)

As we saw in chapter 2.1., non-growing cells were protected from both antibiotic action and immune system. Importantly, growth resumption correlated with the bactericidal action of complement system (I, Fig. 1). Next, we learned that, depending on the growth conditions, the growth resumption of bacteria was impaired by missing the function of RelA (II, Fig. 1). This could, in fact, mean that inhibition of RelA would result in better survival both innate immunity and antibiotic treatment. Indeed, $\Delta relA$ cells were better protected against ampicillin killing than wild-type (II, Fig. 5C and 5D). Yet there are several lines of evidence that stringent response is important to efficient infection (see chapter 1.2.5). Furthermore, decreasing the levels of (p)ppGpp – e.g. combinatorial treatment with subinhibitory levels of chloramphenicol – could render wild-type cells as susceptible to cell wall inhibitors as $\Delta relA$ strain (Kusser & Ishiguro, 1985). Quite some effort is therefore put into search for stringent response inhibitors. Regardless if the inhibitors would be of some immediate value to medicine, specific inhibitors of stringent response would be powerful tools for studies of bacterial physiology.

Although some nucleotide (Wexselblatt *et al.*, 2012) and peptide (de la Fuente-Núñez *et al.*, 2014) based inhibitors are reported, there is more work to be done as they either lack the potency (nucleotide Relacin is required at around 1–5 mM (Gaca *et al.*, 2015; Wexselblatt *et al.*, 2012)) or lack the specificity altogether (Andresen *et al.*, 2016). Therefore, we set up a High Throughput Screening (HTS) assay for stringent response inhibitors. We decided to overcome both purified target-based HTS and phenotype-based HTS limitations and opt for target-based whole-cell HTS (Farha & Brown, 2015) as described in the following.

We used *B. subtilis* because intracellular uptake, a major hurdle for drug discovery, is more efficient through Gram-positive than Gram-negative cell

envelope (Brown & Wright, 2016; Payne *et al.*, 2007; Tommasi *et al.*, 2015). *B. subtilis* has one long bifunctional Rel_{Bsu} and two small alarmone synthetases RelQ (synonyms: SAS1, YjbM) and RelP (synonyms: SAS2, YwaC) (Atkinson *et al.*, 2011; Nanamiya *et al.*, 2008). To reduce the obscuring redundancy in sources of (p)ppGpp, we used the strain that lacks both SASs (designated Δ SAS). For the strategy of screening, we took advantage of the amino acid auxotrophy of *B. subtilis* that lacks (p)ppGpp altogether – in accordance to published report (Kriel *et al.*, 2014), Δ SAS and ppGpp⁰ strains (Δ rel Δ SAS) grow efficiently in defined medium (S7) containing all amino acids except lysine (S7-K) (III, Fig. 1A). In contrast, Δ SAS strain grows equally well yet ppGpp⁰ strain fails to do so when medium lacks valine (S7-V) (III, Fig. 1B). This allowed us to opt for two-stage strategy using Δ SAS strain. Initially, we screened in S7-V medium, in which case we picked up not only potential Rel_{Bsu} inhibitors but also off-target and general inhibitors of cell growth. Hits from the first stage, were then subjected to screening in both S7-V and S7-K media, the chemical compounds inhibiting growth equally well in the two media were considered as off-target. In other words, only the ones inhibiting the growth in S7-V but not in S7-K should be considered as specific inhibitors of Rel_{Bsu} and subjected to further dose-response characterization.

Out of 17,500 synthetic drug-like low molecular weight compounds, we continued with 480 to the second stage. In second stage, twelve compounds were identified as general antibacterials since they inhibited *B. subtilis* Δ SAS equally well in both S7-V and S7-K media (III, STable 1). Five compounds, however, were slightly inhibitory in S7-V while there was no effect in S7-K, suggesting that these could be the specific inhibitors. Importantly, all the five shared the same core, 4-(6-(phenoxy)alkyl)-3,5-dimethyl-1H-pyrazole (III, Table 1). Unfortunately, both dose-response (III, Fig. 3 and SFig. 5) and *in vitro* reconstituted ppGpp synthesis assay (III, SFig. 6) indicated those five compounds were also general antibacterials.

In summary, we developed a robust and specific assay for stringent response inhibitors which resulted in discovery of some general antibacterials and awaits applications to other chemical libraries or natural products (Harvey *et al.*, 2015).

CONCLUSIONS

- A subpopulation of uropathogenic *E. coli* cells growing in human serum is refractory to killing by complement system
- Non-growing and rapidly growing UPEC cells, despite being recognized by the complement system, are protected from the action of human serum
- Only non-growing UPEC cells survive simultaneous treatment with serum and different classes of antibiotics (ampicillin, norfloxacin, and amikacin)
- A culture of stringent response deficient *E. coli*, i.e. relaxed strain, is defective in growth resumption rendering cells non-growing for longer periods of time in growth supporting environment
- The growth resumption defect of relaxed strain of *E. coli* is a function of both the amino acid and carbon source composition of the medium
- In comparison with wild-type, relaxed strain survives ampicillin treatment better even if the growth resumption of the two strains is equal
- A screening system was established for compounds specifically inhibiting stringent response, it failed to yield the desired compound but resulted in identification of novel class of antibacterials, derivatives of 4-(6-(phenoxy)alkyl)-3,5-dimethyl-1H-pyrazole

LIST OF REFERENCES

- Abranches, J., Martinez, A. R., Kajfasz, J. K., Chávez, V., Garsin, D. a & Lemos, J. a. (2009).** The molecular alarmone (p)ppGpp mediates stress responses, vancomycin tolerance, and virulence in *Enterococcus faecalis*. *J Bacteriol* **191**, 2248–56. PMID:19168608.
- Acosta, R. & Lueking, D. R. (1987).** Stringency in the absence of ppGpp accumulation in *Rhodobacter sphaeroides*. *J Bacteriol* **169**, 908–12. PMID:3492491.
- Agirrezabala, X., Fernández, I. S., Kelley, A. C., Cartón, D. G., Ramakrishnan, V. & Valle, M. (2013).** The ribosome triggers the stringent response by RelA via a highly distorted tRNA. *EMBO Rep* **14**, 811–6. PMID:23877429.
- Aiso, T., Yoshida, H., Wada, A. & Ohki, R. (2005).** Modulation of mRNA stability participates in stationary-phase-specific expression of ribosome modulation factor. *J Bacteriol* **187**, 1951–1958.
- Aizenman, E., Engelberg-Kulka, H. & Glaser, G. (1996).** An *Escherichia coli* chromosomal ‘addiction module’ regulated by guanosine [corrected] 3’,5’-bispyrophosphate: a model for programmed bacterial cell death. *PNAS* **93**, 6059–6063. PMID:8650219.
- Akanuma, G., Kazo, Y., Tagami, K., Hiraoka, H., Yano, K., Suzuki, S., Hanai, R., Nanamiya, H., Kato-Yamada, Y. & Kawamura, F. (2016).** Ribosome dimerization is essential for the efficient regrowth of *Bacillus subtilis*. *Microbiology* **162**, 448–58. PMID:26743942.
- Akerlund, T., Nordström, K. & Bernander, R. (1995).** Analysis of cell size and DNA content in exponentially growing and stationary-phase batch cultures of *Escherichia coli*. *J Bacteriol* **177**, 6791–7. PMID:7592469.
- Albertson, N. H., Nyström, T. & Kjelleberg, S. (1990).** Macromolecular synthesis during recovery of the marine *Vibrio* sp. S14 from starvation. *J Gen Microbiol* **136**, 2201–2207. Microbiology Society.
- Alföldi, L., Stent, G. S., Hoogs, M. & Hill, R. (1963).** Physiological effects of the RNA control (RC) gene in *E. coli*. *Z Vererbungsl* **94**, 285–302. PMID:14095092.
- Allison, K. R., Brynildsen, M. P. & Collins, J. J. (2011a).** Metabolite-enabled eradication of bacterial persisters by aminoglycosides. *Nature* **473**, 216–220. PMID:21562562.
- Allison, K. R., Brynildsen, M. P. & Collins, J. J. (2011b).** Heterogeneous bacterial persisters and engineering approaches to eliminate them. *Curr Opin Microbiol* **14**, 593–8. Elsevier Ltd: PMID:21937262.
- Amato, S. M., Fazen, C. H., Henry, T. C., Mok, W. W. K., Orman, M. A., Sandvik, E. L., Volzing, K. G. & Brynildsen, M. P. (2014).** The role of metabolism in bacterial persistence. *Front Microbiol* **5**, 1–9. PMID:24624123.
- Amemiya, K. (1991).** Conserved sequence elements upstream and downstream from the transcription initiation site of the *Caulobacter crescentus* *rrnA* gene cluster. *J Mol Biol* **217**, 751–2. PMID:2005623.
- Amy, P. S., Pauling, C. & Morita, R. Y. (1983).** Recovery from nutrient starvation by a marine *Vibrio* sp. *Appl Environ Microbiol* **45**, 1685–90. PMID:6191662.
- An, G., Justesen, J., Watson, R. J. & Friesen, J. D. (1979).** Cloning the *spoT* gene of *Escherichia coli*: identification of the *spoT* gene product. *J Bacteriol* **137**, 1100–1110.

- Andresen, L., Tenson, T. & Hauryliuk, V. (2016).** Cationic bactericidal peptide 1018 does not specifically target the stringent response alarmone (p)ppGpp. *Sci Rep* **6**, 36549. Nature Publishing Group: PMID:27819280.
- Aravind, L. & Koonin, E. V. (1998).** The HD domain defines a new superfamily of metal-dependent phosphohydrolases. *Trends Biochem Sci* **23**, 469–72. PMID: 9868367.
- Arenz, S., Abdelshahid, M., Sohmen, D., Payoe, R., Starosta, A. L., Berninghausen, O., Hauryliuk, V., Beckmann, R. & Wilson, D. N. (2016).** The stringent factor RelA adopts an open conformation on the ribosome to stimulate ppGpp synthesis. *Nucleic Acids Res* **44**, 6471–6481. PMID:27226493.
- Atherly, A. G. (1979).** Escherichia coli mutant containing a large deletion from relA to argA. *J Bacteriol* **138**, 530–4. PMID:374393.
- Atkinson, G. C., Tenson, T. & Hauryliuk, V. (2011).** The RelA/SpoT Homolog (RSH) Superfamily: Distribution and Functional Evolution of ppGpp Synthetases and Hydrolases across the Tree of Life. *PLoS One* **6**, e23479.
- Avarbock, D., Avarbock, A. & Rubin, H. (2000).** Differential regulation of opposing RelMtb activities by the aminoacylation state of a tRNA.ribosome.mRNA.RelMtb complex. *Biochemistry* **39**, 11640–8. PMID:10995231.
- Balaban, N. Q. (2011).** Persistence: mechanisms for triggering and enhancing phenotypic variability. *Curr Opin Genet Dev* **21**, 768–75. PMID:22051606.
- Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L. & Leibler, S. (2004).** Bacterial persistence as a phenotypic switch. *Science* **305**, 1622–1625. PMID:15308767.
- Ball, C. A., Osuna, R., Ferguson, K. C. & Johnson, R. C. (1992).** Dramatic changes in Fis levels upon nutrient upshift in Escherichia coli. *J Bacteriol* **174**, 8043–56. PMID:1459953.
- Ballesteros, M., Fredriksson, A., Henriksson, J. & Nyström, T. (2001).** Bacterial senescence: protein oxidation in non-proliferating cells is dictated by the accuracy of the ribosomes. *EMBO J* **20**, 5280–9. PMID:11566891.
- Battesti, A. & Bouveret, E. (2006).** Acyl carrier protein/SpoT interaction, the switch linking SpoT-dependent stress response to fatty acid metabolism. *Mol Microbiol* **62**, 1048–1063. PMID:17078815.
- Bättig, P., Hathaway, L. J., Hofer, S. & Mühlemann, K. (2006).** Serotype-specific invasiveness and colonization prevalence in Streptococcus pneumoniae correlate with the lag phase during in vitro growth. *Microbes Infect* **8**, 2612–2617. PMID: 16938479.
- Belitsky, B. & Kari, C. (1982).** Absence of accumulation of ppGpp and RNA during amino acid starvation in Rhizobium meliloti. *J Biol Chem* **257**, 4677–9. PMID: 6175641.
- Beljantseva, J., Kudrin, P., Jimmy, S., Ehn, M., Pohl, R., Varik, V., Tozawa, Y., Shingler, V., Tenson, T. & other authors. (2017a).** Molecular mutagenesis of ppGpp: turning a RelA activator into an inhibitor. *Sci Rep* **7**, 41839. Nature Publishing Group: PMID:28157202.
- Beljantseva, J., Kudrin, P., Andresen, L., Shingler, V., Atkinson, G. C., Tenson, T. & Hauryliuk, V. (2017b).** Negative allosteric regulation of Enterococcus faecalis small alarmone synthetase RelQ by single-stranded RNA. *PNAS* **114**, 3726–3731. PMID:28320944.
- Bigger, J. W. (1944).** Treatment of staphylococcal infections with penicillin. *Lancet* **244**, 497–500. PMID:6638975.

- Bipatnath, M., Dennis, P. P. & Bremer, H. (1998).** Initiation and velocity of chromosome replication in *Escherichia coli* B/r and K-12. *J Bacteriol* **180**, 265–73. PMID:9440515.
- Boaretti, M., Lleò, M. M., Bonato, B., Signoretto, C. & Canepari, P. (2003).** Involvement of *rpoS* in the survival of *Escherichia coli* in the viable but non-culturable state. *Environ Microbiol* **5**, 986–996.
- Bochner, B. R. & Ames, B. N. (1982).** Complete analysis of cellular nucleotides by two-dimensional thin layer chromatography. *J Biol Chem* **257**, 9759–69. PMID:6286632.
- Böck, A., Faiman, L. E. & Neidhardt, F. C. (1966).** Biochemical and genetic characterization of a mutant of *Escherichia coli* with a temperature-sensitive valyl ribonucleic acid synthetase. *J Bacteriol* **92**, 1076–82. PMID:5333025.
- Boes, N., Schreiber, K. & Schobert, M. (2008).** SpoT-triggered stringent response controls *usp* gene expression in *Pseudomonas aeruginosa*. *J Bacteriol* **190**, 7189–99. PMID:18776018.
- Bogatyeva, N. S., Finkelstein, A. V & Galzitskaya, O. V. (2006).** Trend of amino acid composition of proteins of different taxa. *J Bioinform Comput Biol* **4**, 597–608. PMID:16819805.
- Boutte, C. C. & Crosson, S. (2011).** The complex logic of stringent response regulation in *Caulobacter crescentus*: starvation signalling in an oligotrophic environment. *Mol Microbiol* **80**, 695–714. PMID:21338423.
- Boutte, C. C. & Crosson, S. (2013).** Bacterial lifestyle shapes stringent response activation. *Trends Microbiol* **21**, 174–80. PMID:23419217.
- Boye, E. & Løbner-Olesen, A. (1991).** Bacterial growth control studied by flow cytometry. *Res Microbiol* **142**, 131–5. PMID:1925010.
- Braedt, G. & Gallant, J. (1977).** Role of the *rel* gene product in the control of cyclic adenosine 3',5'-monophosphate accumulation. *J Bacteriol* **129**, 564–6. PMID:187574.
- Brauner, A., Fridman, O., Gefen, O. & Balaban, N. Q. (2016).** Distinguishing between resistance, tolerance and persistence to antibiotic treatment. *Nat Rev Microbiol* **14**, 320–330. Nature Publishing Group: PMID:27080241.
- Bremer, H. & Dennis, P. (2008).** Feedback control of ribosome function in *Escherichia coli*. *Biochimie* **90**, 493–499.
- Bremer, H. & Dennis, P. (1996).** Modulation of chemical composition and other parameters of the cell by growth rate. In *Escherichia coli Salmonella Cell Mol Biol*, pp. 1553–1569. Edited by F. C. Neidhardt. Washington, D.C.: Am Soc Microbiol.
- Brown, A., Fernández, I. S., Gordiyenko, Y. & Ramakrishnan, V. (2016).** Ribosome-dependent activation of stringent control. *Nature* **534**, 277–80. Nature Publishing Group: PMID:27279228.
- Brown, E. D. & Wright, G. D. (2016).** Antibacterial drug discovery in the resistance era. *Nature* **529**, 336–343. PMID:26791724.
- Brunschede, H., Dove, T. L. & Bremer, H. (1977).** Establishment of exponential growth after a nutritional shift-up in *Escherichia coli* B/r: accumulation of deoxyribonucleic acid, ribonucleic acid, and protein. *J Bacteriol* **129**, 1020–33. PMID:320174.
- Buchanan, R. E. (1918).** Life Phases in a Bacterial Culture. *J Infect Dis* **23**, 109–125.
- Buckstein, M. H., He, J. & Rubin, H. (2008).** Characterization of nucleotide pools as a function of physiological state in *Escherichia coli*. *J Bacteriol* **190**, 718–26. PMID:17965154.

- Campbell, A. (1957).** Synchronization of cell division. *Bacteriol Rev* **21**, 263–72. PMID:13488884.
- Cheverton, A. M., Gollan, B., Przydacz, M., Wong, C. T., Mylona, A., Hare, S. A. & Helaine, S. (2016).** A Salmonella Toxin Promotes Persister Formation through Acetylation of tRNA. *Mol Cell* **63**, 86–96. The Authors: PMID:27264868.
- Chiaverotti, T. A., Parker, G., Gallant, J. & Agabian, N. (1981).** Conditions that trigger guanosine tetraphosphate accumulation in *Caulobacter crescentus*. *J Bacteriol* **145**, 1463–5. PMID:7204347.
- Christensen, S. K. & Gerdes, K. (2003).** RelE toxins from bacteria and Archaea cleave mRNAs on translating ribosomes, which are rescued by tmRNA. *Mol Microbiol* **48**, 1389–400. PMID:12787364.
- Christensen, S. K. & Gerdes, K. (2004).** Delayed-relaxed response explained by hyperactivation of RelE. *Mol Microbiol* **53**, 587–97. PMID:15228536.
- Cochran, J. W. & Byrne, R. W. (1974).** Isolation and properties of a ribosome-bound factor required for ppGpp and ppGpp synthesis in *Escherichia coli*. *J Biol Chem* **249**, 353–60. PMID:4358548.
- Cohen, N. R., Lobritz, M. a & Collins, J. J. (2013).** Microbial persistence and the road to drug resistance. *Cell Host Microbe* **13**, 632–42. Elsevier Inc.: PMID:23768488.
- Cooper, S. (1997).** Does the initiation mass for DNA replication in *Escherichia coli* vary with growth rate? *Mol Microbiol* **26**, 1138–41. PMID:9426149.
- Cooper, S. & Helmstetter, C. E. (1968).** Chromosome replication and the division cycle of *Escherichia coli* B/r. *J Mol Biol* **31**, 519–40. PMID:4866337.
- Dahl, J. L., Kraus, C. N., Boshoff, H. I. M., Doan, B., Foley, K., Avarbock, D., Kaplan, G., Mizrahi, V., Rubin, H. & Barry, C. E. (2003).** The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of *Mycobacterium tuberculosis* in mice. *PNAS* **100**, 10026–31. PMID:12897239.
- Dalebroux, Z. D., Svensson, S. L., Gaynor, E. C. & Swanson, M. S. (2010).** ppGpp conjures bacterial virulence. *Microbiol Mol Biol Rev* **74**, 171–99. PMID:20508246.
- Das, B., Pal, R. R., Bag, S. & Bhadra, R. K. (2009).** Stringent response in *Vibrio cholerae*: genetic analysis of spoT gene function and identification of a novel (p)ppGpp synthetase gene. *Mol Microbiol* **72**, 380–98. PMID:19298370.
- Dennis, P. P. & Nomura, M. (1974).** Stringent control of ribosomal protein gene expression in *Escherichia coli*. *PNAS* **71**, 3819–23. PMID:4610562.
- Dennis, P. P., Ehrenberg, M. & Bremer, H. (2004).** Control of rRNA synthesis in *Escherichia coli*: a systems biology approach. *Microbiol Mol Biol Rev* **68**, 639–668. PMID:15590778.
- Dennis, P. P. & Bremer, H. (1974).** Differential rate of ribosomal protein synthesis in *Escherichia coli* B/r. *J Mol Biol* **84**, 407–22. PMID:4618855.
- Desnues, B., Cuny, C., Grégori, G., Dukan, S., Aguilaniu, H. & Nyström, T. (2003).** Differential oxidative damage and expression of stress defence regulons in culturable and non-culturable *Escherichia coli* cells. *EMBO Rep* **4**, 400–404. PMID:12671690.
- Diderichsen, B., Fiil, N. P. & Lavallé, R. (1977).** Genetics of the relB locus in *Escherichia coli*. *J Bacteriol* **131**, 30–3. PMID:326765.
- Dittmar, K. A., Sørensen, M. A., Elf, J., Ehrenberg, M. & Pan, T. (2005).** Selective charging of tRNA isoacceptors induced by amino-acid starvation. *EMBO Rep* **6**, 151–7. PMID:15678157.

- Doherty, G. P., Fogg, M. J., Wilkinson, A. J. & Lewis, P. J. (2010).** Small subunits of RNA polymerase: localization, levels and implications for core enzyme composition. *Microbiology* **156**, 3532–43.
- Donachie, W. D. (1968).** Relationship between cell size and time of initiation of DNA replication. *Nature* **219**, 1077–9. PMID:4876941.
- Dozot, M., Boigegrain, R.-A., Delrue, R.-M., Hallez, R., Ouahrani-Bettache, S., Danese, I., Letesson, J.-J., De Bolle, X. & Köhler, S. (2006).** The stringent response mediator Rsh is required for *Brucella melitensis* and *Brucella suis* virulence, and for expression of the type IV secretion system virB. *Cell Microbiol* **8**, 1791–802. PMID:16803581.
- Drecktrah, D., Lybecker, M., Popitsch, N., Rescheneder, P., Hall, L. S. & Samuels, D. S. (2015).** The *Borrelia burgdorferi* RelA/SpoT Homolog and Stringent Response Regulate Survival in the Tick Vector and Global Gene Expression during Starvation. *PLoS Pathog* **11**, e1005160. PMID:26371761.
- Dukan, S. & Nyström, T. (1999).** Oxidative stress defense and deterioration of growth-arrested *Escherichia coli* cells. *J Biol Chem* **274**, 26027–32. PMID:10473549.
- Dukan, S. & Nystrom, T. (1998).** Bacterial senescence: stasis results in increased and differential oxidation of cytoplasmic proteins leading to developmental induction of the heat shock regulon. *Genes Dev* **12**, 3431–3441. PMID:9808629.
- Eccleston, E. D. & Gray, E. D. (1973).** Variations in ppGpp levels in *Rhodospseudomonas spheroides* during adaptation to decreased light intensity. *Biochem Biophys Res Commun* **54**, 1370–6. PMID:4754715.
- Edwards, A. N., Patterson-Fortin, L. M., Vakulskas, C. a, Mercante, J. W., Potrykus, K., Vinella, D., Camacho, M. I., Fields, J. a, Thompson, S. a & other authors. (2011).** Circuitry linking the Csr and stringent response global regulatory systems. *Mol Microbiol* **80**, 1561–80. PMID:21488981.
- Ehrenberg, M. & Kurland, C. G. (1984).** Costs of accuracy determined by a maximal growth rate constraint. *Q Rev Biophys* **17**, 45–82. PMID:6484121.
- English, B. P., Haurlyuk, V., Sanamrad, A., Tankov, S., Dekker, N. H. & Elf, J. (2011).** Single-molecule investigations of the stringent response machinery in living bacterial cells. *PNAS* **108**, E365-73. PMID:21730169.
- Ezekiel, D. H. (1964).** Intracellular charging of soluble ribonucleic acid in *Escherichia coli* subjected to isoleucine starvation and chloramphenicol treatment. *Biochem Biophys Res Commun* **14**, 64–8. PMID:4284348.
- Farha, M. A. & Brown, E. D. (2015).** Unconventional screening approaches for antibiotic discovery. *Ann NY Acad Sci* **1354**, 54–66. PMID:26100135.
- Fiil, N. & Friesen, J. D. (1968).** Isolation of ‘relaxed’ mutants of *Escherichia coli*. *J Bacteriol* **95**, 729–31. PMID:4867755.
- Fiil, N. P., Willumsen, B. M., Friesen, J. D. & von Meyenburg, K. (1977).** Interaction of alleles of the *relA*, *relC* and *spoT* genes in *Escherichia coli*: analysis of the interconversion of GTP, ppGpp and pppGpp. *Mol Gen Genet* **150**, 87–101. PMID:319345.
- Filutowicz, M., Ross, W., Wild, J. & Gourse, R. L. (1992).** Involvement of *fis* protein in replication of the *Escherichia coli* chromosome. *J Bacteriol* **174**, 398–407. PMID:1309527.
- Finkel, S. E. & Kolter, R. (1999).** Evolution of microbial diversity during prolonged starvation. *PNAS* **96**, 4023–7. PMID:10097156.
- Finkel, T. & Holbrook, N. J. (2000).** Oxidants, oxidative stress and the biology of ageing. *Nature* **408**, 239–47. PMID:11089981.

- Flardh, K. & Kjelleberg, S. (1994).** Glucose upshift of carbon-starved marine *Vibrio* sp. strain S14 causes amino acid starvation and induction of the stringent response. *J Bacteriol* **176**, 5897–5903. PMID:7928949.
- Freundlich, M. (1977).** Cyclic AMP can replace the *relA*-dependent requirement for derepression of acetohydroxy acid synthase in *E. coli* K-12. *Cell* **12**, 1121–6. PMID:202392.
- Fridman, O., Goldberg, A., Ronin, I., Shores, N. & Balaban, N. Q. (2014).** Optimization of lag time underlies antibiotic tolerance in evolved bacterial populations. *Nature* **513**, 418–21. Nature Publishing Group: PMID:25043002.
- Friesen, J. D., Fiil, N. P., Parker, J. M. & Haseltine, W. A. (1974).** A new relaxed mutant of *Escherichia coli* with an altered 50S ribosomal subunit. *Proc Natl Acad Sci USA* **71**, 3465–3469. PMID:4610577.
- Friesen, J. D., Fiil, N. P. & von Meyenburg, K. (1975).** Synthesis and turnover of basal level guanosine tetraphosphate in *Escherichia coli*. *J Biol Chem* **250**, 304–9. PMID:1095568.
- Friesen, J. D., An, G. & Fiil, N. P. (1978).** Nonsense and insertion mutants in the *relA* gene of *E. coli*: Cloning *relA*. *Cell* **15**, 1187–1197. PMID:365354.
- Frimodt-Møller, N., Sebbesen, O. & Frølund Thomsen, V. (1983).** The pneumococcus and the mouse protection test: importance of the lag phase in vivo. *Chemotherapy* **29**, 128–34. PMID:6839864.
- Gaca, A. O., Abranches, J., Kajfasz, J. K. & Lemos, J. A. (2012).** Global transcriptional analysis of the stringent response in *Enterococcus faecalis*. *Microbiology* **158**, 1994–2004. PMID:22653948.
- Gaca, A. O., Kudrin, P., Colomer-Winter, C., Beljantseva, J., Liu, K., Anderson, B., Wang, J. D., Rejman, D., Potrykus, K. & other authors. (2015).** From (p)ppGpp to (pp)pGpp: Characterization of Regulatory Effects of pGpp Synthesized by the Small Alarmone Synthetase of *Enterococcus faecalis*. *J Bacteriol* **197**, 2908–19 (V. J. DiRita, Ed.). PMID:26124242.
- Gallant, J., Margason, G. & Finch, B. (1972).** On the turnover of ppGpp in *Escherichia coli*. *J Biol Chem* **247**, 6055–8. PMID:4568601.
- Gallant, J., Palmer, L. & Pao, C. C. (1977).** Anomalous synthesis of ppGpp in growing cells. *Cell* **11**, 181–5. PMID:326415.
- Gallant, J., Erlich, H., Hall, B. & Laffler, T. (1970).** Analysis of the RC Function. *Cold Spring Harb Symp Quant Biol* **35**, 397–405.
- Galton, F. (1879).** The geometric mean, in vital and social statistics. *Proc R Soc London* **29**, 365–367.
- Gausing, K. (1977).** Regulation of ribosome production in *Escherichia coli*: synthesis and stability of ribosomal RNA and of ribosomal protein messenger RNA at different growth rates. *J Mol Biol* **115**, 335–54. PMID:338910.
- Gaynor, E. C., Wells, D. H., MacKichan, J. K. & Falkow, S. (2005).** The *Campylobacter jejuni* stringent response controls specific stress survival and virulence-associated phenotypes. *Mol Microbiol* **56**, 8–27. PMID:15773975.
- Gentry, D. R., Hernandez, V. J., Nguyen, L. H., Jensen, D. B. & Cashel, M. (1993).** Synthesis of the stationary-phase sigma factor sigma^s is positively regulated by ppGpp. *J Bacteriol* **175**, 7982–9. PMID:8253685.
- Germain, E., Roghanian, M., Gerdes, K. & Maisonneuve, E. (2015).** Stochastic induction of persister cells by HipA through (p)ppGpp-mediated activation of mRNA endonucleases. *PNAS* **112**, 5171–5176. PMID:25848049.

- Goodell, W. & Tomasz, A. (1980).** Alteration of *Escherichia coli* murein during amino acid starvation. *J Bacteriol* **144**, 1009–16. PMID:6777363.
- Gropp, M., Strausz, Y., Gross, M. & Glaser, G. (2001).** Regulation of *Escherichia coli* RelA requires oligomerization of the C-terminal domain. *J Bacteriol* **183**, 570–579.
- Hansen, S., Lewis, K. & Vulić, M. (2008).** Role of global regulators and nucleotide metabolism in antibiotic tolerance in *Escherichia coli*. *Antimicrob Agents Chemother* **52**, 2718–26. PMID:18519731.
- Harms, A., Maisonneuve, E. & Gerdes, K. (2016).** Mechanisms of bacterial persistence during stress and antibiotic exposure. *Science* **354**, aaf4268–aaf4268. PMID:27980159.
- Harris, B. Z., Kaiser, D. & Singer, M. (1998).** The guanosine nucleotide (p)ppGpp initiates development and A-factor production in *myxococcus xanthus*. *Genes {&} Dev* **12**, 1022–1035. PMID:9531539.
- Harshman, R. B. & Yamazaki, H. (1971).** Formation of ppGpp in a relaxed and stringent strain of *Escherichia coli* during diauxic lag. *Biochemistry* **10**, 3980–3982. PMID:4946193.
- Harshman, R. B. & Yamazaki, H. (1972).** MSI accumulation induced by sodium chloride. *Biochemistry* **11**, 615–8. PMID:4551894.
- Harvey, A. L., Edrada-Ebel, R. & Quinn, R. J. (2015).** The re-emergence of natural products for drug discovery in the genomics era. *Nat Rev Drug Discov* **14**, 111–29. PMID:25614221.
- Haseltine, W. A. & Block, R. (1973).** Synthesis of guanosine tetra- and pentaphosphate requires the presence of a codon-specific, uncharged transfer ribonucleic acid in the acceptor site of ribosomes. *PNAS* **70**, 1564–8. PMID:4576025.
- Haseltine, W. A., Block, R., Gilbert, W. & Weber, K. (1972).** MSI and MSII made on Ribosome in Idling Step of Protein Synthesis. *Nature* **238**, 381–384. PMID:4559580.
- Hathaway, L. J., Brugger, S. D., Morand, B., Bangert, M., Rotzetter, J. U., Hauser, C., Graber, W. A., Gore, S., Kadioglu, A. & Mühlemann, K. (2012).** Capsule type of *Streptococcus pneumoniae* determines growth phenotype. *PLoS Pathog* **8**. PMID:22412375.
- Hava, D. L. & Camilli, A. (2002).** Large-scale identification of serotype 4 *Streptococcus pneumoniae* virulence factors. *Mol Microbiol* **45**, 1389–406. PMID:12207705.
- Heinemeyer, E. A. & Richter, D. (1977).** In vitro degradation of guanosine tetraphosphate (ppGpp) by an enzyme associated with the ribosomal fraction from *Escherichia coli*. *FEBS Lett* **84**, 357–61. PMID:340264.
- Heinemeyer, E. A., Geis, M. & Richter, D. (1978).** Degradation of guanosine 3'-diphosphate 5'-diphosphate in vitro by the spoT gene product of *Escherichia coli*. *Eur J Biochem* **89**, 125–31. PMID:359325.
- Heinemeyer, E. A. & Richter, D. (1978).** Characterization of the guanosine 5'-triphosphate 3'-diphosphate and guanosine 5'-diphosphate 3'-diphosphate degradation reaction catalyzed by a specific pyrophosphorylase from *Escherichia coli*. *Biochemistry* **17**, 5368–72. PMID:365225.
- Helmstetter, C. E. & Cooper, S. (1968).** Rate of DNA synthesis during the division cycle of *Escherichia coli* B/r. *J Mol Biol* **31**, 507–518. PMID:4866336.
- Hengge-Aronis, R. (1993).** Survival of hunger and stress: The role of rpoS in early stationary phase gene regulation in *E. coli*. *Cell* **72**, 165–168. PMID:8425216.

- Hengge, R. (2011).** Stationary-Phase Gene Regulation in *Escherichia coli*. *EcoSal Plus* **4**.
- Hill, N. S., Kadoya, R., Chatteraj, D. K. & Levin, P. A. (2012).** Cell size and the initiation of DNA replication in bacteria. *PLoS Genet* **8**, e1002549 (W. F. Burkholder, Ed.). PMID:22396664.
- Howorth & England. (1999).** Accumulation of ppGpp in symbiotic and free-living nitrogen-fixing bacteria following amino acid starvation. *Arch Microbiol* **171**, 131–4. PMID:9914311.
- Hsu, D., Shih, L. M. & Zee, Y. C. (1994).** Degradation of rRNA in *Salmonella* strains: a novel mechanism to regulate the concentrations of rRNA and ribosomes. *J Bacteriol* **176**, 4761–5. PMID:8045909.
- Huisman, G. W., Siegele, D. A., Zambrano, M. M. & Kolter, R. (1996).** Morphological and physiological changes during stationary phase. *Escherichia coli Salmonella Cell Mol Biol* **2**, 1672–1682.
- Izutsu, K., Wada, A. & Wada, C. (2001).** Expression of ribosome modulation factor (RMF) in *Escherichia coli* requires ppGpp. *Genes Cells* **6**, 665–76. PMID:11532026.
- Jacobson, A. & Gillespie, D. (1968).** Metabolic events occurring during recovery from prolonged glucose starvation in *Escherichia coli*. *J Bacteriol* **95**, 1030–9. PMID:4868350.
- Jenkins, D. E., Schultz, J. E. & Matin, A. (1988).** Starvation-induced cross protection against heat or H₂O₂ challenge in *Escherichia coli*. *J Bacteriol* **170**, 3910–4. PMID:3045081.
- Jenkins, D. E., Chaisson, S. A. & Matin, A. (1990).** Starvation-induced cross protection against osmotic challenge in *Escherichia coli*. *J Bacteriol* **172**, 2779–81. PMID:2185233.
- Jiang, M., Sullivan, S. M., Wout, P. K. & Maddock, J. R. (2007).** G-protein control of the ribosome-associated stress response protein SpoT. *J Bacteriol* **189**, 6140–7. PMID:17616600.
- Jøers, A., Kaldalu, N. & Tenson, T. (2010).** The frequency of persisters in *Escherichia coli* reflects the kinetics of awakening from dormancy. *J Bacteriol* **192**, 3379–84. PMID:20435730.
- Johansson, J., Balsalobre, C., Wang, S. Y., Urbonaviciene, J., Jin, D. J., Sondén, B. & Uhlin, B. E. (2000).** Nucleoid proteins stimulate stringently controlled bacterial promoters: a link between the cAMP-CRP and the (p)ppGpp regulons in *Escherichia coli*. *Cell* **102**, 475–85. PMID:10966109.
- Johnson, G. S., Adler, C. R., Collins, J. J. & Court, D. (1979).** Role of the spoT gene product and manganese ion in the metabolism of guanosine 5'-diphosphate 3'-diphosphate in *Escherichia coli*. *J Biol Chem* **254**, 5483–7. PMID:376509.
- Justesen, J., Lund, T., Skou Pedersen, F. & Kjeldgaard, N. O. (1986).** The physiology of stringent factor (ATP:GTP 3'-diphosphotransferase) in *Escherichia coli*. *Biochimie* **68**, 715–22. PMID:3015258.
- Kaldalu, N., Hauryluk, V. & Tenson, T. (2016).** Persisters – as elusive as ever. *Appl Microbiol Biotechnol* **100**, 6545–6553. Applied Microbiology and Biotechnology: PMID:27262568.
- Kaspy, I., Rotem, E., Weiss, N., Ronin, I., Balaban, N. Q. & Glaser, G. (2013).** HipA-mediated antibiotic persistence via phosphorylation of the glutamyl-tRNA-synthetase. *Nat Commun* **4**, 3001. Nature Publishing Group: PMID:24343429.

- Kazmierczak, K. M., Wayne, K. J., Rechtsteiner, A. & Winkler, M. E. (2009).** Roles of rel(Spn) in stringent response, global regulation and virulence of serotype 2 *Streptococcus pneumoniae* D39. *Mol Microbiol* **72**, 590–611. PMID:19426208.
- Keren, I., Kaldalu, N., Spoering, A., Wang, Y. & Lewis, K. (2004a).** Persister cells and tolerance to antimicrobials. *FEMS Microbiol Lett* **230**, 13–8. PMID:14734160.
- Keren, I., Shah, D., Spoering, A., Kaldalu, N. & Lewis, K. (2004b).** Specialized persister cells and the mechanism of multidrug tolerance in *Escherichia coli*. *J Bacteriol* **186**, 8172–80. PMID:15576765.
- Kjeldgaard, N. O., Maaloe, O. & Schaechter, M. (1958).** The Transition Between Different Physiological States During Balanced Growth of *Salmonella typhimurium*. *J Gen Microbiol* **19**, 607–616. PMID:13611203.
- Klumpp, S., Scott, M., Pedersen, S. & Hwa, T. (2013).** Molecular crowding limits translation and cell growth. *PNAS* **110**, 16754–9. PMID:24082144.
- Kriel, A., Brinsmade, S. R., Tse, J. L., Tehranchi, A. K., Bittner, A. N., Sonenshein, A. L. & Wang, J. D. (2014).** GTP dysregulation in *Bacillus subtilis* cells lacking (p)ppGpp results in phenotypic amino acid auxotrophy and failure to adapt to nutrient downshift and regulate biosynthesis genes. *J Bacteriol* **196**, 189–201. PMID:24163341.
- Kuroda, A., Murphy, H., Cashel, M. & Kornberg, A. (1997).** Guanosine tetra- and pentaphosphate promote accumulation of inorganic polyphosphate in *Escherichia coli*. *J Biol Chem* **272**, 21240–3. PMID:9261133.
- Kusser, W. & Ishiguro, E. E. (1985).** Involvement of the relA gene in the autolysis of *Escherichia coli* induced by inhibitors of peptidoglycan biosynthesis. *J Bacteriol* **164**, 861–5. PMID:3902801.
- Kusser, W. & Ishiguro, E. E. (1987).** Suppression of mutations conferring penicillin tolerance by interference with the stringent control mechanism of *Escherichia coli*. *J Bacteriol* **169**, 4396–8. PMID:3305487.
- de la Fuente-Núñez, C., Reffuveille, F., Haney, E. F., Straus, S. K. & Hancock, R. E. W. (2014).** Broad-spectrum anti-biofilm peptide that targets a cellular stress response. *PLoS Pathog* **10**, e1004152. PMID:24852171.
- Laffler, T. & Gallant, J. (1974).** spoT, a new genetic locus involved in the stringent response in *E. coli*. *Cell* **1**, 27–30.
- Lafleur, M. D., Qi, Q. & Lewis, K. (2010).** Patients with long-term oral carriage harbor high-persister mutants of *Candida albicans*. *Antimicrob Agents Chemother* **54**, 39–44. PMID:19841146.
- Lange, R. & Hengge-Aronis, R. (1991a).** Growth phase-regulated expression of bolA and morphology of stationary-phase *Escherichia coli* cells are controlled by the novel sigma factor sigma S. *J Bacteriol* **173**, 4474–81. PMID:1648559.
- Lange, R. & Hengge-Aronis, R. (1991b).** Identification of a central regulator of stationary-phase gene expression in *Escherichia coli*. *Mol Microbiol* **5**, 49–59. PMID:1849609.
- Lazzarini, R. A., Cashel, M. & Gallant, J. (1971).** On the regulation of guanosine tetraphosphate levels in stringent and relaxed strains of *Escherichia coli*. *J Biol Chem* **246**, 4381–5. PMID:4937124.
- Leckie, M. P., Tieber, V. L., Porter, S. E. & Dietzler, D. N. (1980).** The relA gene is not required for glycogen accumulation during NH₄⁺ starvation of *Escherichia coli*. *Biochem Biophys Res Commun* **95**, 924–931. PMID:6998477.

- Lemaux, P. G., Herendeen, S. L., Bloch, P. L. & Neidhardt, F. C. (1978).** Transient rates of synthesis of individual polypeptides in *E. coli* following temperature shifts. *Cell* **13**, 427–34. PMID:350413.
- Lemonnier, M., Levin, B. R., Romeo, T., Garner, K., Baquero, M.-R., Mercante, J., Lemichez, E., Baquero, F. & Blázquez, J. (2008).** The evolution of contact-dependent inhibition in non-growing populations of *Escherichia coli*. *Proceedings Biol Sci* **275**, 3–10. PMID:17956846.
- Lemos, J. A., Lin, V. K., Nascimento, M. M., Abranches, J. & Burne, R. A. (2007).** Three gene products govern (p)ppGpp production by *Streptococcus mutans*. *Mol Microbiol* **65**, 1568–81. PMID:17714452.
- Lesley, J. a & Shapiro, L. (2008).** SpoT regulates DnaA stability and initiation of DNA replication in carbon-starved *Caulobacter crescentus*. *J Bacteriol* **190**, 6867–80. PMID:18723629.
- Lewis, K. (2007).** Persister cells, dormancy and infectious disease. *Nat Rev Microbiol* **5**, 48–56. PMID:17143318.
- Lewis, K. (2010).** Persister cells. *Annu Rev Microbiol* **64**, 357–72. PMID:20528688.
- Li, W., Bouveret, E., Zhang, Y., Liu, K., Wang, J. D. & Weisshaar, J. C. (2016).** Effects of amino acid starvation on RelA diffusive behavior in live *Escherichia coli*. *Mol Microbiol* **99**, 571–85. PMID:26480956.
- Li, X., Yagi, M., Morita, T. & Aiba, H. (2008).** Cleavage of mRNAs and role of tmRNA system under amino acid starvation in *Escherichia coli*. *Mol Microbiol* **68**, 462–473. PMID:18284591.
- Loewen, P. C. & Hengge-Aronis, R. (1994).** The role of the sigma factor sigma S (KatF) in bacterial global regulation. *Annu Rev Microbiol* **48**, 53–80. PMID:7826018.
- Luidalepp, H., Jöers, A., Kaldalu, N. & Tenson, T. (2011).** Age of inoculum strongly influences persister frequency and can mask effects of mutations implicated in altered persistence. *J Bacteriol* **193**, 3598–605. PMID:21602347.
- Lund, E. & Kjeldgaard, N. O. (1972).** Metabolism of guanosine tetraphosphate in *Escherichia coli*. *Eur J Biochem* **28**, 316–326. PMID:4562599.
- Maciag, M., Kochanowska, M., Lyzeń, R., Wegrzyn, G. & Szalewska-Palasz, A. (2010).** ppGpp inhibits the activity of *Escherichia coli* DnaG primase. *Plasmid* **63**, 61–7. PMID:19945481.
- Madar, D., Dekel, E., Bren, A., Zimmer, A., Porat, Z. & Alon, U. (2013).** Promoter activity dynamics in the lag phase of *Escherichia coli*. *BMC Syst Biol* **7**, 136. PMID:24378036.
- Maisonneuve, E. & Gerdes, K. (2014).** Molecular mechanisms underlying bacterial persisters. *Cell* **157**, 539–48. Elsevier Inc.: PMID:24766804.
- Maisonneuve, E., Castro-Camargo, M. & Gerdes, K. (2013).** (p)ppGpp controls bacterial persistence by stochastic induction of toxin-antitoxin activity. *Cell* **154**, 1140–50. Elsevier Inc.: PMID:23993101.
- Maiväli, Ü., Paier, A. & Tenson, T. (2013).** When stable RNA becomes unstable: degradation of ribosomes in bacteria and beyond. *Biol Chem* **394**, 845–55. PMID:23612597.
- Martínez-Costa, O. H., Fernández-Moreno, M. A. & Malpartida, F. (1998).** The *relA/spoT*-homologous gene in *Streptomyces coelicolor* encodes both ribosome-dependent (p)ppGpp-synthesizing and -degrading activities. *J Bacteriol* **180**, 4123–32. PMID:9696759.

- Matin, A. (1991).** The molecular basis of carbon-starvation-induced general resistance in *Escherichia coli*. *Mol Microbiol* **5**, 3–10. PMID:2014002.
- McAlister, D. (1879).** The law of the geometric mean. *Proc R Soc London* **29**, 367–376.
- McCann, M. P., Kidwell, J. P. & Matin, A. (1991).** The putative sigma factor KatF has a central role in development of starvation-mediated general resistance in *Escherichia coli*. *J Bacteriol* **173**, 4188–4194.
- Mechold, U., Potrykus, K., Murphy, H., Murakami, K. S. & Cashel, M. (2013).** Differential regulation by ppGpp versus pppGpp in *Escherichia coli*. *Nucleic Acids Res.*
- Metzger, S., Schreiber, G., Aizenman, E., Cashel, M. & Glaser, G. (1989).** Characterization of the *relA1* mutation and a comparison of *relA1* with new *relA* null alleles in *Escherichia coli*. *J Biol Chem* **264**, 21146–52. PMID:2556396.
- Mitchell, J. J. & Lucas-Lenard, J. M. (1980).** The effect of alcohols on guanosine 5'-diphosphate-3'-diphosphate metabolism in stringent and relaxed *Escherichia coli*. *J Biol Chem* **255**, 6307–13. PMID:6156159.
- Mobley, H. L., Green, D. M., Trifillis, A. L., Johnson, D. E., Chippendale, G. R., Lockett, C. V, Jones, B. D. & Warren, J. W. (1990).** Pyelonephritogenic *Escherichia coli* and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains. *Infect Immun* **58**, 1281–9. PMID:2182540.
- Monod, J. (1949).** The growth of bacterial cultures. *Annu Rev Microbiol* **3**, 371–394.
- Morris, D. W. & DeMoss, J. A. (1965).** Role of aminoacyl-transfer ribonucleic acid in the regulation of ribonucleic acid synthesis in *Escherichia coli*. *J Bacteriol* **90**, 1624–1631. PMID:5322722.
- Mouery, K., Rader, B. a, Gaynor, E. C. & Guillemin, K. (2006).** The stringent response is required for *Helicobacter pylori* survival of stationary phase, exposure to acid, and aerobic shock. *J Bacteriol* **188**, 5494–500. PMID:16855239.
- Moyed, H. S. & Bertrand, K. P. (1983).** *hipA*, a newly recognized gene of *Escherichia coli* K-12 that affects frequency of persistence after inhibition of murein synthesis. *J Bacteriol* **155**, 768–775. PMID:6348026.
- Mulcahy, L. R., Burns, J. L., Lory, S. & Lewis, K. (2010).** Emergence of *Pseudomonas aeruginosa* strains producing high levels of persister cells in patients with cystic fibrosis. *J Bacteriol* **192**, 6191–9. PMID:20935098.
- Murray, H. D., Schneider, D. a & Gourse, R. L. (2003).** Control of rRNA expression by small molecules is dynamic and nonredundant. *Mol Cell* **12**, 125–34. PMID:12887898.
- Murray, K. D. & Bremer, H. (1996).** Control of *spoT*-dependent ppGpp synthesis and degradation in *Escherichia coli*. *J Mol Biol* **259**, 41–57. PMID:8648647.
- Nakada, D. & Marquisee, M. J. (1965).** Relaxed synthesis of ribosomal RNA by a stringent strain of *Escherichia coli*. *J Mol Biol* **13**, 351–61. Academic Press Inc. (London) Ltd.: PMID:5325726.
- Nanamiya, H., Kasai, K., Nozawa, A., Yun, C.-S., Narisawa, T., Murakami, K., Natori, Y., Kawamura, F. & Tozawa, Y. (2008).** Identification and functional analysis of novel (p)ppGpp synthetase genes in *Bacillus subtilis*. *Mol Microbiol* **67**, 291–304. PMID:18067544.
- Neidhardt, F. & Umbarger, H. (1996).** Chemical composition of *Escherichia coli*. In *Escherichia coli Salmonella*, pp. 13–16.
- Neidhardt, F. C. (2006).** Apples, oranges and unknown fruit. *Nat Rev Microbiol* **4**, 876. PMID:17120340.

- Nielsen, H. J., Youngren, B., Hansen, F. G. & Austin, S. (2007).** Dynamics of *Escherichia coli* chromosome segregation during multifork replication. *J Bacteriol* **189**, 8660–6. PMID:17905986.
- Nilsson, L., Vanet, a, Vijgenboom, E. & Bosch, L. (1990).** The role of FIS in trans activation of stable RNA operons of *E. coli*. *EMBO J* **9**, 727–734. PMID:1690124.
- Ninnemann, O., Koch, C. & Kahmann, R. (1992).** The *E. coli* *fis* promoter is subject to stringent control and autoregulation. *EMBO J* **11**, 1075–83. PMID:1547773.
- Nyström, T., Larsson, C. & Gustafsson, L. (1996).** Bacterial defense against aging: role of the *Escherichia coli* ArcA regulator in gene expression, readjusted energy flux and survival during stasis. *EMBO J* **15**, 3219–28. PMID:8670822.
- Nyström, T. (2005).** Role of oxidative carbonylation in protein quality control and senescence. *EMBO J* **24**, 1311–1317. PMID:15775985.
- O'Farrell, P. H. (1978).** The suppression of defective translation by ppGpp and its role in the stringent response. *Cell* **14**, 545–57. PMID:357011.
- Okayasu, T., Ikeda, M., Akimoto, K. & Sorimachi, K. (1997).** The amino acid composition of mammalian and bacterial cells. *Amino Acids* **13**, 379–391.
- Oliver, J. D. (2005).** The viable but nonculturable state in bacteria. *J Microbiol* **43 Spec No**, 93–100. PMID:15765062.
- Österberg, S., Peso-Santos, T. del & Shingler, V. (2011).** Regulation of Alternative Sigma Factor Use. *Annu Rev Microbiol* **65**, 37–55. PMID:21639785.
- Osuna, R., Lienau, D., Hughes, K. T. & Johnson, R. C. (1995).** Sequence, regulation, and functions of *fis* in *Salmonella typhimurium*. *J Bacteriol* **177**, 2021–32. PMID:7536730.
- Parker, J., Watson, R. J. & Friesen, J. D. (1976).** A relaxed mutant with an altered ribosomal protein L11. *Mol Gen Genet* **144**, 111–4. PMID:772409.
- Paul, B. J., Ross, W., Gaal, T. & Gourse, R. L. (2004).** rRNA transcription in *Escherichia coli*. *Annu Rev Genet* **38**, 749–70. PMID:15568992.
- Paul, B. J., Berkmen, M. B. & Gourse, R. L. (2005).** DksA potentiates direct activation of amino acid promoters by ppGpp. *PNAS* **102**, 7823–7828. PMID:15899978.
- Payne, D. J., Gwynn, M. N., Holmes, D. J. & Pompliano, D. L. (2007).** Drugs for bad bugs: confronting the challenges of antibacterial discovery. *Nat Rev Drug Discov* **6**, 29–40. PMID:17159923.
- Pedersen, F. S. & Kjeldgaard, N. O. (1977).** Analysis of the *relA* gene product of *Escherichia coli*. *Eur J Biochem* **76**, 91–7. PMID:195816.
- Pedersen, F. S., Lund, E. & Kjeldgaard, N. O. (1973).** Codon specific, tRNA dependent in vitro synthesis of ppGpp and pppGpp. *Nat New Biol* **243**, 13–15. PMID:17319071.
- Peterson, C. N., Mandel, M. J. & Silhavy, T. J. (2005).** *Escherichia coli* starvation diets: essential nutrients weigh in distinctly. *J Bacteriol* **187**, 7549–53. PMID:16267278.
- Pisabarro, A. G., De Pedro, M. A. & Ishiguro, E. E. (1990).** Dissociation of the ampicillin-induced lysis of amino acid-deprived *Escherichia coli* into two stages. *J Bacteriol* **172**, 2187–90. PMID:2180921.
- Postgate, J. R. (1994).** *The outer reaches of life*. Cambridge university press.
- Potrykus, K., Murphy, H., Philippe, N. & Cashel, M. (2010).** ppGpp is the major source of growth rate control in *E. coli*. *Environ Microbiol* **13**, 563–575. PMID:20946586.

- Primm, T. P., Andersen, S. J., Mizrahi, V., Avarbock, D., Rubin, H. & Barry, C. E. (2000).** The stringent response of *Mycobacterium tuberculosis* is required for long-term survival. *J Bacteriol* **182**, 4889–98. PMID:10940033.
- Rao, N. N., Liu, S. & Kornberg, A. (1998).** Inorganic polyphosphate in *Escherichia coli*: the phosphate regulon and the stringent response. *J Bacteriol* **180**, 2186–93. PMID:9555903.
- Rao, N. N. & Kornberg, A. (1996).** Inorganic polyphosphate supports resistance and survival of stationary-phase *Escherichia coli*. *J Bacteriol* **178**, 1394–400. PMID:8631717.
- Raskin, D. M., Judson, N. & Mekalanos, J. J. (2007).** Regulation of the stringent response is the essential function of the conserved bacterial G protein CgtA in *Vibrio cholerae*. *PNAS* **104**, 4636–4641. PMID:17360576.
- Raskó, I. & Alföldi, L. (1971).** Biosynthetic L-threonine deaminase as the origin of L-serine sensitivity of *Escherichia coli*. *Eur J Biochem* **21**, 424–7. PMID:4936450.
- Reeve, C. A., Bockman, A. T. & Matin, A. (1984).** Role of protein degradation in the survival of carbon-starved *Escherichia coli* and *Salmonella typhimurium*. *J Bacteriol* **157**, 758–63. PMID:6365890.
- Rheinberger, H. J., Sternbach, H. & Nierhaus, K. H. (1981).** Three tRNA binding sites on *Escherichia coli* ribosomes. *PNAS* **78**, 5310–4. PMID:7029532.
- Richter, D. (1976).** Stringent factor from *Escherichia coli* directs ribosomal binding and release of uncharged tRNA. *PNAS* **73**, 707–11. PMID:768983.
- Richter, D. (1980).** Uncharged tRNA inhibits guanosine 3',5'-bis (diphosphate) 3'-pyrophosphohydrolase [ppGppase], the *spoT* gene product, from *Escherichia coli*. *Mol Gen Genet* **178**, 325–7. PMID:6156378.
- Rodionov, D. G. & Ishiguro, E. E. (1995).** Direct correlation between overproduction of guanosine 3',5'-bispyrophosphate (ppGpp) and penicillin tolerance in *Escherichia coli*. *J Bacteriol* **177**, 4224–9.
- Rojiani, M. V, Jakubowski, H. & Goldman, E. (1990).** Relationship between protein synthesis and concentrations of charged and uncharged tRNA^{Trp} in *Escherichia coli*. *PNAS* **87**, 1511–5. PMID:2106136.
- Rojiani, M. V, Jakubowski, H. & Goldman, E. (1989).** Effect of variation of charged and uncharged tRNA(Trp) levels on ppGpp synthesis in *Escherichia coli*. *J Bacteriol* **171**, 6493–502. PMID:2687238.
- Rolfe, M. D., Rice, C. J., Lucchini, S., Pin, C., Thompson, A., Cameron, A. D. S., Alston, M., Stringer, M. F., Betts, R. P. & other authors. (2012).** Lag phase is a distinct growth phase that prepares bacteria for exponential growth and involves transient metal accumulation. *J Bacteriol* **194**, 686–701. PMID:22139505.
- Romeo, T. & Preiss, J. (1989).** Genetic regulation of glycogen biosynthesis in *Escherichia coli*: in vitro effects of cyclic AMP and guanosine 5'-diphosphate 3'-diphosphate and analysis of in vivo transcripts. *J Bacteriol* **171**, 2773–82. PMID:2468650.
- Ronneau, S., Petit, K., De Bolle, X. & Hallez, R. (2016).** Phosphotransferase-dependent accumulation of (p)ppGpp in response to glutamine deprivation in *Caulobacter crescentus*. *Nat Commun* **7**, 11423. PMID:27109061.
- Roostalu, J., Jõers, A., Luidalepp, H., Kaldalu, N. & Tenson, T. (2008).** Cell division in *Escherichia coli* cultures monitored at single cell resolution. *BMC Microbiol* **8**, 68. PMID:18430255.

- Ross, W., Thompson, J. F., Newlands, J. T. & Gourse, R. L. (1990).** E.coli Fis protein activates ribosomal RNA transcription in vitro and in vivo. *EMBO J* **9**, 3733–42. PMID:2209559.
- Russell, J. B. & Cook, G. M. (1995).** Energetics of bacterial growth: balance of anabolic and catabolic reactions. *Microbiol Rev* **59**, 48–62. PMID:7708012.
- Russo, T. A., Stapleton, A., Wenderoth, S., Hooton, T. M. & Stamm, W. E. (1995).** Chromosomal restriction fragment length polymorphism analysis of Escherichia coli strains causing recurrent urinary tract infections in young women. *J Infect Dis* **172**, 440–5. PMID:7622887.
- Ryals, J., Little, R. & Bremer, H. (1982).** Control of rRNA and tRNA syntheses in Escherichia coli by guanosine tetraphosphate. *J Bacteriol* **151**, 1261–8. PMID: 6179924.
- Rymer, R. U., Solorio, F. A., Tehranchi, A. K., Chu, C., Corn, J. E., Keck, J. L., Wang, J. D. & Berger, J. M. (2012).** Binding Mechanism of Metal-NTP Substrates and Stringent-Response Alarmones to Bacterial DnaG-Type Primases. *Structure* **20**, 1478–1489. Elsevier Ltd: PMID:22795082.
- Saint-Ruf, C. & Matic, I. (2006).** Environmental tuning of mutation rates. *Environ Microbiol* **8**, 2058–2058.
- Schaechter, M., MaalOe, O. & Kjeldgaard, N. O. (1958).** Dependency on Medium and Temperature of Cell Size and Chemical Composition during Balanced Growth of Salmonella typhimurium. *J Gen Microbiol* **19**, 592–606. PMID:13611202.
- Schaechter, M., Williamson, J. P., Hood, J. R. & Koch, A. L. (1962).** Growth, cell and nuclear divisions in some bacteria. *J Gen Microbiol* **29**, 421–34. PMID: 13976593.
- Schellhorn, H. E. (2014).** Elucidating the function of the RpoS regulon. *Future Microbiol* **9**, 497–507. PMID:24810349.
- Schilling-Bartetzko, S., Franceschi, F., Sternbach, H. & Nierhaus, K. H. (1992).** Apparent association constants of tRNAs for the ribosomal A, P, and E sites. *J Biol Chem* **267**, 4693–702. PMID:1537852.
- Schreiber, G., Metzger, S., Aizenman, E., Roza, S., Cashel, M. & Glaser, G. (1991).** Overexpression of the relA gene in Escherichia coli. *J Biol Chem* **266**, 3760–7. PMID:1899866.
- Schumacher, M. A., Balani, P., Min, J., Chinnam, N. B., Hansen, S., Vulić, M., Lewis, K. & Brennan, R. G. (2015).** HipBA-promoter structures reveal the basis of heritable multidrug tolerance. *Nature* **524**, 59–64. PMID:26222023.
- Scoarughi, G. L., Cimmino, C. & Donini, P. (1999).** Helicobacter pylori: a eubacterium lacking the stringent response. *J Bacteriol* **181**, 552–5. PMID:9882669.
- Seyfzadeh, M., Keener, J. & Nomura, M. (1993).** spoT-dependent accumulation of guanosine tetraphosphate in response to fatty acid starvation in Escherichia coli. *PNAS* **90**, 11004–11008. PMID:7504290.
- Sezonov, G., Joseleau-Petit, D. & D’Ari, R. (2007).** Escherichia coli physiology in Luria-Bertani broth. *J Bacteriol* **189**, 8746–9. PMID:17905994.
- Shyp, V., Tankov, S., Ermakov, A., Kudrin, P., English, B. P., Ehrenberg, M., Tenson, T., Elf, J. & Haurlyliuk, V. (2012).** Positive allosteric feedback regulation of the stringent response enzyme RelA by its product. *EMBO Rep* **13**, 835–9. PMID:22814757.
- Silva, A. J. & Benitez, J. A. (2006).** A Vibrio cholerae relaxed (relA) mutant expresses major virulence factors, exhibits biofilm formation and motility, and colonizes the suckling mouse intestine. *J Bacteriol* **188**, 794–800. PMID:16385069.

- Somerville, C. R. & Ahmed, A. (1979).** Mutants of *Escherichia coli* defective in the degradation of guanosine 5'-triphosphate, 3'-diphosphate (pppGpp). *Mol Gen Genet* **169**, 315–23. PMID:372753.
- Song, M., Kim, H.-J., Kim, E. Y., Shin, M., Lee, H. C., Hong, Y., Rhee, J. H., Yoon, H., Ryu, S. & other authors. (2004).** ppGpp-dependent Stationary Phase Induction of Genes on *Salmonella* Pathogenicity Island 1. *J Biol Chem* **279**, 34183–34190. PMID:15161921.
- Sørensen, M. A. (2001).** Charging levels of four tRNA species in *Escherichia coli* Rel(+) and Rel(-) strains during amino acid starvation: a simple model for the effect of ppGpp on translational accuracy. *J Mol Biol* **307**, 785–98. PMID:11273701.
- Sørensen, M. A., Jensen, K. F. & Pedersen, S. (1994).** High concentrations of ppGpp decrease the RNA chain growth rate. Implications for protein synthesis and translational fidelity during amino acid starvation in *Escherichia coli*. *J Mol Biol* **236**, 441–54. PMID:7508988.
- Spira, B., Silberstein, N. & Yagil, E. (1995).** Guanosine 3',5'-bispyrophosphate (ppGpp) synthesis in cells of *Escherichia coli* starved for Pi. *J Bacteriol* **177**, 4053–8. PMID:7608079.
- Stallings, C. L., Stephanou, N. C., Chu, L., Hochschild, A., Nickels, B. E. & Glickman, M. S. (2009).** CarD is an essential regulator of rRNA transcription required for *Mycobacterium tuberculosis* persistence. *Cell* **138**, 146–59. Elsevier Ltd: PMID:19596241.
- Stamminger, G. & Lazzarini, R. A. (1974).** Altered metabolism of the guanosine tetraphosphate, ppGpp, in mutants of *E. coli*. *Cell* **1**, 85–90.
- Steinchen, W., Schuhmacher, J. S., Altegoer, F., Fage, C. D., Srinivasan, V., Linne, U., Marahiel, M. A. & Bange, G. (2015).** Catalytic mechanism and allosteric regulation of an oligomeric (p)ppGpp synthetase by an alarmone. *PNAS* **112**, 13348–53. PMID:26460002.
- Stent, G. S. & Brenner, S. (1961).** A genetic locus for the regulation of ribonucleic acid synthesis. *PNAS* **47**, 2005–14. PMID:13916843.
- Strauch, E., Takano, E., Baylis, H. A. & Bibb, M. J. (1991).** The stringent response in *Streptomyces coelicolor* A3(2). *Mol Microbiol* **5**, 289–98. PMID:1710311.
- Sun, W., Roland, K. L., Branger, C. G., Kuang, X. & Curtiss, R. (2009).** The role of relA and spoT in *Yersinia pestis* KIM5 pathogenicity. *PLoS One* **4**, e6720. PMID:19701461.
- Svitil, A. L., Cashel, M. & Zyskind, J. W. (1993).** Guanosine tetraphosphate inhibits protein synthesis in vivo. A possible protective mechanism for starvation stress in *Escherichia coli*. *J Biol Chem* **268**, 2307–11. PMID:8428905.
- Swinnen, I. A. M., Bernaerts, K., Dens, E. J. J., Geeraerd, A. H. & Van Impe, J. F. (2004).** Predictive modelling of the microbial lag phase: a review. *Int J Food Microbiol* **94**, 137–59. PMID:15193801.
- Sy, J., Ogawa, Y. & Lipmann, F. (1973).** Nonribosomal synthesis of guanosine 5',3'-polyphosphates by the ribosomal wash of stringent *Escherichia coli*. *PNAS* **70**, 2145–8. PMID:4579015.
- Sy, J. (1977).** In vitro degradation of guanosine 5'-diphosphate, 3'-diphosphate. *PNAS* **74**, 5529–5533. PMID:414222.
- Sy, J. & Lipmann, F. (1973).** Identification of the synthesis of guanosine tetraphosphate (MS I) as insertion of a pyrophosphoryl group into the 3'-position in guanosine 5'-diphosphate. *PNAS* **70**, 306–9. PMID:4346881.

- Syal, K., Joshi, H., Chatterji, D. & Jain, V. (2015).** Novel pppGpp binding site at the C-terminal region of the Rel enzyme from *Mycobacterium smegmatis*. *FEBS J* **282**, 3773–85. PMID:26179484.
- Taguchi, M., Izui, K. & Katsuki, H. (1980).** Augmentation of glycogen synthesis under stringent control in *Escherichia coli*. *J Biochem* **88**, 379–387. PMID:6998975.
- Tedin, K. & Norel, F. (2001).** Comparison of DeltarefA strains of *Escherichia coli* and *Salmonella enterica* serovar Typhimurium suggests a role for ppGpp in attenuation regulation of branched-chain amino acid biosynthesis. *J Bacteriol* **183**, 6184–96. PMID:11591661.
- Tian, C., Roghanian, M., Jørgensen, M. G., Sneppen, K., Sørensen, M. A., Gerdes, K. & Mitarai, N. (2016).** Rapid Curtailing of the Stringent Response by Toxin-Antitoxin Encoded mRNases. *J Bacteriol* **198**, JB.00062-16. PMID:27137501.
- Tommasi, R., Brown, D. G., Walkup, G. K., Manchester, J. I. & Miller, A. A. (2015).** ESKAPEing the labyrinth of antibacterial discovery. *Nat Publ Gr* 1–14. Nature Publishing Group.
- Torrey, H. L., Keren, I., Via, L. E., Lee, J. S. & Lewis, K. (2016).** High Persister Mutants in *Mycobacterium tuberculosis*. *PLoS One* **11**, e0155127. PMID:27176494.
- Traxler, M. F., Summers, S. M., Nguyen, H.-T., Zacharia, V. M., Hightower, G. A., Smith, J. T. & Conway, T. (2008).** The global, ppGpp-mediated stringent response to amino acid starvation in *Escherichia coli*. *Mol Microbiol* **68**, 1128–48. PMID:18430135.
- Trigui, H., Dudyk, P., Oh, J., Hong, J.-I. & Faucher, S. P. (2014).** A regulatory feedback loop between RpoS and SpoT supports the survival of *Legionella pneumophila* in water. *Appl Environ Microbiol*. PMID:25416763.
- Typas, A., Becker, G. & Hengge, R. (2007).** The molecular basis of selective promoter activation by the σ^{70} subunit of RNA polymerase. *Mol Microbiol* **63**, 1296–1306. PMID:17302812.
- Ueta, M., Yoshida, H., Wada, C., Baba, T., Mori, H. & Wada, A. (2005).** Ribosome binding proteins YhbH and YfiA have opposite functions during 100S formation in the stationary phase of *Escherichia coli*. *Genes Cells* **10**, 1103–12. PMID:16324148.
- Vanderwel, D. & Ishiguro, E. E. (1984).** Properties of cell wall peptidoglycan synthesized by amino acid deprived relA mutants of *Escherichia coli*. *Can J Microbiol* **30**, 1239–1246. PMID:6391642.
- Vinella, D., Albrecht, C., Cashel, M. & D'Ari, R. (2005).** Iron limitation induces SpoT-dependent accumulation of ppGpp in *Escherichia coli*. *Mol Microbiol* **56**, 958–70. PMID:15853883.
- Wada, A. (1998).** Growth phase coupled modulation of *Escherichia coli* ribosomes. *Genes Cells* **3**, 203–208.
- Wada, A., Yamazaki, Y., Fujita, N. & Ishihama, A. (1990).** Structure and probable genetic location of a 'ribosome modulation factor' associated with 100S ribosomes in stationary-phase *Escherichia coli* cells. *PNAS* **87**, 2657–61. PMID:2181444.
- Wada, A., Igarashi, K., Yoshimura, S., Aimoto, S. & Ishihama, A. (1995).** Ribosome modulation factor: stationary growth phase-specific inhibitor of ribosome functions from *Escherichia coli*. *Biochem Biophys Res Commun* **214**, 410–7. PMID:7677746.
- Wagner, E. G. & Kurland, C. G. (1980).** Translational accuracy enhanced in vitro by (p)ppGpp. *Mol Gen Genet* **180**, 139–45. PMID:6934363.
- Webb, C., Moreno, M., Wilmes-Riesenberg, M., Curtiss, R. & Foster, J. W. (1999).** Effects of DksA and ClpP protease on sigma S production and virulence in *Salmonella typhimurium*. *Mol Microbiol* **34**, 112–23. PMID:10540290.

- Weber, H., Polen, T., Heuveling, J., Wendisch, V. F. & Hengge, R. (2005).** Genome-wide analysis of the general stress response network in *Escherichia coli*: sigmaS-dependent genes, promoters, and sigma factor selectivity. *J Bacteriol* **187**, 1591–1603.
- Wei, B., Shin, S., LaPorte, D., Wolfe, a J. & Romeo, T. (2000).** Global regulatory mutations in *csrA* and *rpoS* cause severe central carbon stress in *Escherichia coli* in the presence of acetate. *J Bacteriol* **182**, 1632–40. PMID:10692369.
- Weichart, D., Querfurth, N., Dreger, M. & Hengge-Aronis, R. (2003).** Global role for ClpP-containing proteases in stationary-phase adaptation of *Escherichia coli*. *J Bacteriol* **185**, 115–25. PMID:12486047.
- Welch, R. A., Burland, V., Plunkett, G., Redford, P., Roesch, P., Rasko, D., Buckles, E. L., Liou, S.-R., Boutin, A. & other authors. (2002).** Extensive mosaic structure revealed by the complete genome sequence of uropathogenic *Escherichia coli*. *PNAS* **99**, 17020–4. PMID:12471157.
- Wells, D. H. & Gaynor, E. C. (2006).** *Helicobacter pylori* initiates the stringent response upon nutrient and pH downshift. *J Bacteriol* **188**, 3726–9. PMID:16672627.
- Wendrich, T. M., Blaha, G., Wilson, D. N., Marahiel, M. a & Nierhaus, K. H. (2002).** Dissection of the mechanism for the stringent factor RelA. *Mol Cell* **10**, 779–88. PMID:12419222.
- Wexselblatt, E., Oppenheimer-Shaanan, Y., Kaspy, I., London, N., Schueler-Furman, O., Yavin, E., Glaser, G., Katzhendler, J. & Ben-Yehuda, S. (2012).** Relacin, a Novel Antibacterial Agent Targeting the Stringent Response. *PLoS Pathog* **8**, e1002925. PMID:23028324.
- Weyer, W. J., de Boer, H. A., de Boer, J. G. & Gruber, M. (1976).** The sequence of ppGpp and pppGpp in the reaction scheme for magic spot synthesis. *Biochim Biophys Acta - Nucleic Acids Protein Synth* **442**, 123–127. PMID:782536.
- Wilson, P. D. G., Wilson, D. R., Brocklehurst, T. F., Coleman, H. P., Mitchell, G., Waspe, C. R., Jukes, S. A. & Robins, M. M. (2003).** Batch growth of *Salmonella typhimurium* LT2: Stoichiometry and factors leading to cessation of growth. *Int J Food Microbiol* **89**, 195–203. PMID:14623385.
- Wold, S., Skarstad, K., Steen, H. B., Stokke, T. & Boye, E. (1994).** The initiation mass for DNA replication in *Escherichia coli* K-12 is dependent on growth rate. *EMBO J* **13**, 2097–102. PMID:8187762.
- Wout, P., Pu, K., Sullivan, S. M., Reese, V., Zhou, S., Lin, B. & Maddock, J. R. (2004).** The *Escherichia coli* GTPase CgtAE cofractionates with the 50S ribosomal subunit and interacts with SpoT, a ppGpp synthetase/hydrolase. *J Bacteriol* **186**, 5249–57. PMID:15292126.
- Xiao, H., Kalman, M., Ikehara, K., Zemel, S., Glaser, G. & Cashel, M. (1991).** Residual guanosine 3',5'-bispyrophosphate synthetic activity of *relA* null mutants can be eliminated by *spoT* null mutations. *J Biol Chem* **266**, 5980–90. PMID:2005134.
- Yamagishi, M., Matsushima, H., Wada, A., Sakagami, M., Fujita, N. & Ishihama, A. (1993).** Regulation of the *Escherichia coli* *rmf* gene encoding the ribosome modulation factor: growth phase- and growth rate-dependent control. *EMBO J* **12**, 625–630.
- Yang, X. & Ishiguro, E. E. (2001a).** Dimerization of the RelA protein of *Escherichia coli*. *Biochem Cell Biol* **79**, 729–36. PMID:11800013.

- Yang, X. & Ishiguro, E. E. (2001b).** Involvement of the N Terminus of Ribosomal Protein L11 in Regulation of the RelA Protein of Escherichia coli Involvement of the N Terminus of Ribosomal Protein L11 in Regulation of the RelA Protein of Escherichia coli †. *J Bacteriol* **183**, 6532–6537.
- Yegian, C. D., Stent, G. S. & Martin, E. M. (1966).** Intracellular condition of Escherichia coli transfer RNA. *PNAS* **55**, 839–46. PMID:5327069.
- Young, R. & Bremer, H. (1976).** Polypeptide-chain-elongation rate in Escherichia coli B/r as a function of growth rate. *Biochem J* **160**, 185–94. PMID:795428.
- Zambrano, M. M. & Kolter, R. (1996).** GASping for Life in Stationary Phase. *Cell* **86**, 181–184. PMID:8706122.
- Zhou, Y. N., Coleman, W. G., Yang, Z., Yang, Y., Hodgson, N., Chen, F. & Jin, D. J. (2008).** Regulation of cell growth during serum starvation and bacterial survival in macrophages by the bifunctional enzyme SpoT in Helicobacter pylori. *J Bacteriol* **190**, 8025–32. PMID:18835987.

SUMMARY IN ESTONIAN

Poomisvastus bakterite kasvus ja elus püsimises

Bakterid peavad ellu jäämiseks pidevalt kohanema oma väliskeskkonnaga. Sobivates tingimustes kasvavad paljud bakteriliigid väga kiiresti. Kiire kasv iseenesest viib aga kasvutingimuste muutumiseni. Nüüd kohtame järgmist bakteritele iseloomulikku omadust – jaksu pikka aega elus püsida kasvaks mittesobivates tingimustes. Seejuures säilitavad nad olulise võime kiiresti taas kasvama hakata, kui keskkonnatingimused paranevad. Muutuvate keskkonnatingimustega kohanemiseks on bakteritel evolutsiooni käigus välja kujunenud hulganisti mehhanisme. Üks selline, keskne ja pea kõigis bakterites esinev mehhanism on poomisvastus. Poomisvastust kutsuvad esile järsud muutused keskkonnas, mis nõuavad kasvu aeglustumist, sageli peatub kasv esialgu täielikult, rakk kohaneb ja kui võimalik, jätkab kasvamist muutunud tingimustes paraja tempoga. Vähemaks reguleeritakse näiteks valgusünteesi masinavärk ning rohkemaks elus püsimise ja autonoomsuse tarbeks oluline – hulganisti kahjustuste eest kaitsevaid süsteeme ja tarvilikud anaboolsed protsessid. Poomisvastust orkestreerivad signaalmolekulid, guanosiin nukleotiidid pppGpp ja ppGpp, koondnimega (p)ppGpp. Nende nukleotiidide sünteesi eest vastutavad *Escherichia coli*-s kaks valku, RelA ja SpoT. Viimane neist hoolitseb ka selle eest, et (p)ppGpp-d oleks rakus parasjagu, s.t SpoT on kahefunktsionaalne, omab ka (p)ppGpp-d lagundavat aktiivsust. Mitmetes teistes bakterites (näiteks *Bacillus subtilis*) on poomisvastuse tarbeks vaid üks peamine kahefunktsionaalne ensüüm (Rel_{Bsu}), aga ka hiljuti avastatud väikesed valgud, millest on veel vähe teada ja mis omavad kas sünteesi või hüdroolüüsi aktiivsust.

Arvestades poomisvastuse ulatuslikku mõju bakteriraku füsioloogiale, ei tule vast üllatusena, et see protsess mõjutab bakterite võimet põhjustada haigust ja antibiootikumide võimet infektsiooni ravida. Antibiootikumide kasutamise algusaegadest peale pandi tähele, et sugugi mitte kõik bakterirakud ei sure baktereid tapva antibiootikumi toimel, üksikud bakterid jäävad ikka elama. Erinevalt antibiootikumi resistentsusest ei kasva sellised rakud antibiootikumi juuresolekul, nad lihtsalt taluvad, elavad üle, ja neid nimetatakse persistoriteks. Ka persistorite moodustumises on nähtud poomisvastuse rolli – kui suurem osa bakteritest kasvab jõudsalt, lülitub üksikutes siiski millegipärast sisse poomisvastus. Oletatakse, et persistorid võivad antibiootikumi kuuri lõppedes põhjustada haiguse taastekkimist. Haigusest jagu saamisel on aga antibiootikumiga võrdväärne roll kanda immuunsüsteemil, mis võiks ju jagu saada sellistest mittejagunevatest persistoritest. Samas on vähe teada selliste persistor-rakkude ja immuunsüsteemi vahelistest seostest, mida asutigi käesolevas töös kõigepealt uurima.

Selgus, et nn kaasasündinud immuunsüsteem inimese vere seerumi komplemendi näol ei tapa sugugi kõiki uropatogeense *E. coli* rakke. Kui nüüd samaaegselt seerumile rakendati ka antibiootikumi töötlust, sõltus tulemus konkreetsest antibiootikumist. Ampitsilliini (rakukesta sünteesi inhibiitor) või amikat-

siini (translatsiooni inhibiitor) lisamisel vähenes seerumis ellujäävate bakterirakkude hulk ühe-kahe suurusjärgu võrra, mis lubab oletada, et mõned rakud, mida seerum ei hävita, tapeti antibiootikumi poolt. Lisaks võimendas seerum amikatsiini toimet subinhibitoorsete kontsentratsioonide puhul. Norfloksatsiini (DNA replikatsiooni inhibiitor) lisamine seerumile ei põhjustanud mingit muutust ellu jäänud bakterirakkude arvukuses, mistõttu võib spekuloida, et komplement ja norfloksatsiin tapavad ühesuguseid rakke.

Uurimaks bakteripopulatsiooni võimaliku heterogeensuse mõju komplemendi süsteemi vahendatud tapmisele, analüüsiti järgmiseks bakterirakkude jagunemist üksikraku tasemel. Katsetulemused näitasid, et kuigi komplement tunneb ära kõik bakterirakud, ja suurem osa bakterirakkudest sureb, jäävad elama keskmisest oluliselt kiiremini kasvavad ja mittekasvavad rakud. Kui nüüd samal ajal rakendada antibiootikumi töötlust (ampitsilliini, amikatsiini või norfloksatsiiniga), jäävad alles vaid mittekasvavad rakud ning kiiremini kasvavad hävitatakse.

Kui võrd katsed seerumiga näitasid muuhulgas, et bakterite suremisel on positiivne korrelatsioon rakkude seerumis kasvama hakkamisega ja mittejagunevad rakud on kaitstud nii antibiootikumi toime kui komplemendi eest, uuriti järgmisena *E. coli* rakkude kasvama hakkamise regulatsiooni ja poomisvastuse rolli selles. Selgus, et rakud, kus puudub peamine poomisvastuse valk RelA (edaspidi $\Delta relA$ tüvi), hakkavad soodsate kasvutingimuste saabudes kasvama neli tundi hiljem metsiktüüpi rakkudest, kui keskkonnas puuduvad aminohapped. Lisaks aminohapetele mõjutab kasvama hakkamist ka süsinikuallikas – $\Delta relA$ tüvi toibus metsiktüüpi tüvest hiljem süsinikuallikana glükoosi sisaldaval söötmel, ent võrdväärselt glütseroolil kasvades. Selgus, et selline RelA funktsiooni puudumine ja toibumisedefekt võib mõjutada antibiootikumi toimet – ampitsilliin tappis glükoosil toibuvaid metsik-tüüpi rakke efektiivsemalt kui $\Delta relA$ rakke. Mõnevõrra üllatuslikult elasid $\Delta relA$ rakud paremini üle ka ampitsilliinitöötuse glütseroolil toibudes. Igatahes, teatud tingimuste korral võib poomisvastus olla vajalik rakkude kiiresti kasvama hakkamiseks, mis omakorda võib mõjutada antibiootikumi toimet neile rakkudele.

Eelpool nägime, et poomisvastusel on roll bakterirakkude kasvama hakkamisel ja see mõjutab antibiootikumi toimet neile rakkudele. Tõsi küll, teatud üsnagi kitsastes tingimustes oli funktsionaalse poomisvastuse puudumine ampitsilliini toime üle elamiseks kasulik. Samas on küllaldaselt töid, mis näitavad, et poomisvastuse puudumise korral on vähenenud bakterite võime haigust põhjustada. Koos antibiootikumi resistentsuse hirmuäratava levikuga otsitakse seepärast ka spetsiifilise poomisvastuse pärssijaid üsna palavikuliselt. Isegi kui neist ei ole peatset ja vahetat kasu meditsiinile, oleksid spetsiifilised inhibiitorid oluline töövahend bakteriraku füsioloogia uurimiseks. Sestap soovisime järgmiseks leida poomisvastuse inhibiitoreid.

Neid otsiti keemiliste ühendite raamatukogust (17500 ühendit), kasutades testsüsteemina bakterit *B. subtilis*, sest ainete sisenemine raku on gram-positiivsetel bakteritel hõlpsam kui gram-negatiivsetel. Otsingu tulemusel leiti 17 uut antibakteriaalset ühendit, kahjuks polnud ükski neist piisavalt spetsiifiline

poomisvastuse suhtes. Jääb üle vaid loota, et välja töötatud kõrge läbilaskevõimega poomisvastuse inhibiitorite testsüsteem annab positiivse tulemuse mõne teise keemiliselt sünteetiliselt ja/või loodusest isoleeritud ühendite raamatukogu puhul.

ACKNOWLEDGEMENTS

My foremost gratitude goes to my supervisor Tanel for being always there whenever I needed an advice and leaving me alone to figure things out on my own the rest of the times. I learned a lot. I thank my second supervisor Vasili for generous introduction to the lures of Northern Sweden, insights into forces shaping the contemporary science, and pushing me to be productive day in day out.

In addition, I would like to thank all the coauthors of the papers presented in the thesis: Sofia, Marta, Karin, Eliisa, Markus, Liis, Steffi, Stina Lindberg and Tozawa Yuzuru. I thank my colleagues from Tenson and Hauryliuk lab and other guys from the Institute of Technology, in Tartu, and Department of Molecular Biology, in Umeå, for great intellectual discussions as well as fun times with me. You all will be heavily missed.

Last, but definitely not least, I would like to thank my family for unconditional support, love, and belief in me, although they had no clue why I'm still a student after all these years – “haven't you learned enough already?” Particularly, I thank my wife Aune for her patience, fortitude and dedication to withstand the countless evenings and weekends I stayed in lab.

PUBLICATIONS

CURRICULUM VITAE

Name: Vallo Varik
Date of birth: October 16, 1981
Citizenship: Estonian
Telephone: +372 526 4034
E-mail: vvarik.mail@gmail.com

EDUCATION

2007–2017 PhD, Biomedical Engineering, supervisor: Professor Tanel Tenson, University of Tartu, Tartu, Estonia
2005–2007 MSc, Molecular and Cell Biology, University of Tartu, Tartu, Estonia
2000–2005 BSc, Genetic Engineering, *cum laude*, University of Tartu, Tartu, Estonia

RESEARCH EXPERIENCE

Umeå University

- Developed bacterial physiology based high-throughput screening assay for antimicrobials from proof of principle to optimization and software for analysis

University of Tartu

- Developed mouse model of bacterial cell division assay on FACS
- Studied bacterial growth physiology during adjustments to changes in environment, stress survival and growth resumption
- Established bacterial nucleotide extraction and detection system on HPLC
- Studied bacterial killing by human serum complement system
- Studied relationship between tRNA and macrolide class of antibiotics

LIST OF PUBLICATIONS

* equal contribution; # corresponding author

Kudrin P*, **Varik V***, Oliveira SRA, Beljantseva J, Del Peso Santos T, Dzhygyr I, Rejman D, Cava F, Tenson T & Hauryliuk V[#]. (2017). Sub-inhibitory concentrations of bacteriostatic antibiotics induce relA-dependent and relA-independent tolerance to β -lactams. *Antimicrob Agents Chemother AAC*. 02173-16. PMID:[28115345](#)

Beljantseva J*, Kudrin P*, Jimmy S, Ehn M, Pohl R, **Varik V**, Tozawa Y, Shingler V, Tenson T, Rejman D[#] & Hauryliuk V[#]. (2017). Molecular mutagenesis of ppGpp: turning a RelA activator into an inhibitor. *Sci Rep* 7, 41839. PMID:[28157202](#)

Andresen L*, **Varik V***, Tozawa Y, Jimmy S, Lindberg S, Tenson T & Hauryliuk V (2016). Auxotrophy-based High Throughput Screening assay for the identification of *Bacillus subtilis* stringent response inhibitors. *Sci Rep* 6, 35824. PMID:[27775002](#).

- Monteferrante CG, Jirgensons A, **Varik V**, Hauryliuk V, Goessens WHF & Hays JP[#] (2016). Evaluation of the characteristics of leucyl-tRNA synthetase (LeuRS) inhibitor AN3365 in combination with different antibiotic classes. *Eur J Clin Microbiol Infect Dis* 35, 1857–1864. PMID:27506217.
- Varik V**[#], Oliveira SRA, Hauryliuk V[#] & Tenson T[#] (2016). Composition of the outgrowth medium modulates wake-up kinetics and ampicillin sensitivity of stringent and relaxed *Escherichia coli*. *Sci Rep* 6, 22308. PMID:26923949.
- Putrinš M, Kogermann K, Lukk E, Lippus M, **Varik V** & Tenson T[#] (2015). Phenotypic heterogeneity enables uropathogenic *Escherichia coli* to evade killing by antibiotics and serum complement. *Infect Immun* 83, 1056–67. PMID:25561706.

ELULOOKIRJELDUS

Nimi: Vallo Varik
Sünniaeg: 16. oktoober, 1981
Kodakondsus: Eesti
Telefon: +372 526 4034
E-post: vvarik.mail@gmail.com

TEENISTUSKÄIK

2015–2017 Projekti assistent, Umeå Ülikool, Umeå, Rootsi
2012–2015 Tehnoloogia spetsialist, Tartu Ülikool, Tartu, Eesti

HARIDUS

2007–2017 PhD, Biomedistiini tehnoloogia, Juhendaja: Professor Tanel Tenson, Tartu Ülikool, Tartu, Estonia
2005–2007 MSc, Molekulaar- ja rakubioloogia, Tartu Ülikool, Tartu, Estonia
2000–2005 BSc, Geenitehnoloogia, *cum laude*, Tartu Ülikool, Tartu, Estonia

PUBLIKATSIOONID

* võrdne panus, # kirjavahetusega tegelev autor

- Kudrin P*, **Varik V***, Oliveira SRA, Beljantseva J, Del Peso Santos T, Dzhygyr I, Rejman D, Cava F, Tenson T & Hauryliuk V[#]. (2017). Sub-inhibitory concentrations of bacteriostatic antibiotics induce relA-dependent and relA-independent tolerance to β -lactams. *Antimicrob Agents Chemother AAC*. 02173-16. PMID:[28115345](#)
- Beljantseva J*, Kudrin P*, Jimmy S, Ehn M, Pohl R, **Varik V**, Tozawa Y, Shingler V, Tenson T, Rejman D[#] & Hauryliuk V[#]. (2017). Molecular mutagenesis of ppGpp: turning a RelA activator into an inhibitor. *Sci Rep* 7, 41839. PMID:[28157202](#)
- Andresen L*, **Varik V***, Tozawa Y, Jimmy S, Lindberg S, Tenson T & Hauryliuk V[#] (2016). Auxotrophy-based High Throughput Screening assay for the identification of *Bacillus subtilis* stringent response inhibitors. *Sci Rep* 6, 35824. PMID:[27775002](#).
- Monteferrante CG, Jirgensons A, **Varik V**, Hauryliuk V, Goessens WHF & Hays JP[#] (2016). Evaluation of the characteristics of leucyl-tRNA synthetase (LeuRS) inhibitor AN3365 in combination with different antibiotic classes. *Eur J Clin Microbiol Infect Dis* 35, 1857–1864. PMID:[27506217](#).
- Varik V***, Oliveira SRA, Hauryliuk V[#] & Tenson T[#] (2016). Composition of the outgrowth medium modulates wake-up kinetics and ampicillin sensitivity of stringent and relaxed *Escherichia coli*. *Sci Rep* 6, 22308. PMID:[26923949](#).
- Putriņš M, Kogermann K, Lukk E, Lippus M, **Varik V** & Tenson T[#] (2015). Phenotypic heterogeneity enables uropathogenic *Escherichia coli* to evade killing by antibiotics and serum complement. *Infect Immun* 83, 1056–67. PMID:[25561706](#).

DISSERTATIONES TECHNOLOGIAE UNIVERSITATIS TARTUENSIS

1. **Imre Mäger.** Characterization of cell-penetrating peptides: Assessment of cellular internalization kinetics, mechanisms and bioactivity. Tartu 2011, 132 p.
2. **Taavi Lehto.** Delivery of nucleic acids by cell-penetrating peptides: application in modulation of gene expression. Tartu 2011, 155 p.
3. **Hannes Luidalepp.** Studies on the antibiotic susceptibility of *Escherichia coli*. Tartu 2012, 111 p.
4. **Vahur Zadin.** Modelling the 3D-microbattery. Tartu 2012, 149 p.
5. **Janno Torop.** Carbide-derived carbon-based electromechanical actuators. Tartu 2012, 113 p.
6. **Julia Suhorutšenko.** Cell-penetrating peptides: cytotoxicity, immunogenicity and application for tumor targeting. Tartu 2012, 139 p.
7. **Viktoryia Shyp.** G nucleotide regulation of translational GTPases and the stringent response factor RelA. Tartu 2012, 105 p.
8. **Mardo Kõivomägi.** Studies on the substrate specificity and multisite phosphorylation mechanisms of cyclin-dependent kinase Cdk1 in *Saccharomyces cerevisiae*. Tartu, 2013, 157 p.
9. **Liis Karo-Astover.** Studies on the Semliki Forest virus replicase protein nsP1. Tartu, 2013, 113 p.
10. **Piret Arukuusk.** NickFects—novel cell-penetrating peptides. Design and uptake mechanism. Tartu, 2013, 124 p.
11. **Piret Villo.** Synthesis of acetogenin analogues. Asymmetric transfer hydrogenation coupled with dynamic kinetic resolution of α -amido- β -keto esters. Tartu, 2013, 151 p.
12. **Villu Kasari.** Bacterial toxin-antitoxin systems: transcriptional cross-activation and characterization of a novel *mqsRA* system. Tartu, 2013, 108 p.
13. **Margus Varjak.** Functional analysis of viral and host components of alphavirus replicase complexes. Tartu, 2013, 151 p.
14. **Liane Viru.** Development and analysis of novel alphavirus-based multi-functional gene therapy and expression systems. Tartu, 2013, 113 p.
15. **Kent Langel.** Cell-penetrating peptide mechanism studies: from peptides to cargo delivery. Tartu, 2014, 115 p.
16. **Rauno Temmer.** Electrochemistry and novel applications of chemically synthesized conductive polymer electrodes. Tartu, 2014, 206 p.
17. **Indrek Must.** Ionic and capacitive electroactive laminates with carbonaceous electrodes as sensors and energy harvesters. Tartu, 2014, 133 p.
18. **Veiko Voolaid.** Aquatic environment: primary reservoir, link, or sink of antibiotic resistance? Tartu, 2014, 79 p.
19. **Kristiina Laanemets.** The role of SLAC1 anion channel and its upstream regulators in stomatal opening and closure of *Arabidopsis thaliana*. Tartu, 2015, 115 p.

20. **Kalle Pärn.** Studies on inducible alphavirus-based antitumour strategy mediated by site-specific delivery with activatable cell-penetrating peptides. Tartu, 2015, 139 p.
21. **Anastasia Selyutina.** When biologist meets chemist: a search for HIV-1 inhibitors. Tartu, 2015, 172 p.
22. **Sirle Saul.** Towards understanding the neurovirulence of Semliki Forest virus. Tartu, 2015, 136 p.
23. **Marit Orav.** Study of the initial amplification of the human papilloma-virus genome. Tartu, 2015, 132 p.
24. **Tormi Reinson.** Studies on the Genome Replication of Human Papilloma-viruses. Tartu, 2016, 110 p.
25. **Mart Ustav Jr.** Molecular Studies of HPV-18 Genome Segregation and Stable Replication. Tartu, 2016, 152 p.
26. **Margit Mutso.** Different Approaches to Counteracting Hepatitis C Virus and Chikungunya Virus Infections. Tartu, 2016, 184 p.
27. **Jelizaveta Geimanen.** Study of the Papillomavirus Genome Replication and Segregation. Tartu, 2016, 168 p.
28. **Mart Toots.** Novel Means to Target Human Papillomavirus Infection. Tartu, 2016, 173 p.
29. **Kadi-Liis Veiman.** Development of cell-penetrating peptides for gene delivery: from transfection in cell cultures to induction of gene expression *in vivo*. Tartu, 2016, 136 p.
30. **Ly Pärnaste.** How, why, what and where: Mechanisms behind CPP/cargo nanocomplexes. Tartu, 2016, 147 p.
31. **Age Utt.** Role of alphavirus replicase in viral RNA synthesis, virus-induced cytotoxicity and recognition of viral infections in host cells. Tartu, 2016, 183 p.
32. **Veiko Vunder.** Modeling and characterization of back-relaxation of ionic electroactive polymer actuators. Tartu, 2016, 154 p.
33. **Piia Kivipõld.** Studies on the Role of Papillomavirus E2 Proteins in Virus DNA Replication. Tartu, 2016, 118 p.
34. **Liina Jakobson.** The roles of abscisic acid, CO₂, and the cuticle in the regulation of plant transpiration. Tartu, 2017, 162 p.
35. **Helen Isok-Paas.** Viral-host interactions in the life cycle of human papillomaviruses. Tartu, 2017, 158 p.
36. **Hanna Hõrak.** Identification of key regulators of stomatal CO₂ signalling via O₃-sensitivity. Tartu, 2017, 160 p.
37. **Jekaterina Jevtuševskaja.** Application of isothermal amplification methods for detection of *Chlamydia trachomatis* directly from biological samples. Tartu, 2017, 96 p.
38. **Ülar Allas.** Ribosome-targeting antibiotics and mechanisms of antibiotic resistance. Tartu, 2017, 152 p.
39. **Anton Paier.** Ribosome Degradation in Living Bacteria. Tartu, 2017, 108 p.